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ABSTRACT 
Despite the efforts towards eradication, malaria remains the most deadly parasitic and vector-borne 
disease, urging for the development of an effective antimalarial vaccine. Recently, a renewed interest 
in Plasmodium attenuated whole-organism vaccine strategies has emerged, long acknowledged to 
experimentally induce full and sterile immunity against malaria in mice, monkeys and humans. This 
approach involves the use of non-replicating but metabolic active sporozoites, either attenuated by 
exposition to radiation, the Radiation-Attenuated Sporozoites (RAS), or by genetic modification, the 
Genetically-Attenuated Sporozoites (GAS). These attenuated parasites are able to infect hepatocytes 
in vivo as normal sporozoites, but are unable to fully develop in the liver. This arrest in development 
has been associated with their apparent failure to prevent host cell apoptosis, which leads to the 
formation of apoptotic bodies filled with parasite antigens. Several pieces of evidence have suggested 
that these apoptotic bodies may provide an optimal source of antigens for dendritic cells cross-
presentation, and therefore, immune response activation. The aim of this project was to assess 
whether apoptosis of RAS or GAS infected hepatocytes is involved in the induced protective immunity 
response against subsequent parasite challenges. Results obtained through the immunization of 
C57BL/6 background caspase-3 deficient mice with P. berghei RAS or p36p- GAS revealed that these 
mice are only partially protected against further infection. These suggest that at least to some extent, 
caspase-3 mediated apoptosis of infected hepatocytes may be important in generation of immunity by 
attenuated parasites. 
Key words: Malaria, Attenuated Parasites, Host Cell Apoptosis, Immunity. 
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RESUMO  
Em pleno século XXI, e apesar de todas as medidas de controlo implementadas ao longo dos 
anos, a malária continua a ser uma das doenças mais mortíferas a assolar a humanidade. Só no ano 
de 2008, a malária foi responsável por 243 milhões de casos de doença e quase um milhão de 
mortes, maioritariamente no continente Africano.  
A malária, ou paludismo, é causada por parasitas pertencentes ao género Plasmodium, um grupo 
de protozoários capazes de infectar grupos diversificados de animais vertebrados como mamíferos, 
aves e répteis. Em humanos, a malária é causada maioritariamente por quatro espécies, P. 
falciparum, P. vivax, P. ovale e P. malariae, e é transmitida através da picada de mosquitos fêmea 
infectados do género Anopheles. Uma vez inoculado no hospedeiro mamífero, o parasita, sob a forma 
de esporozoíto, inicia a fase assexuada do seu ciclo de vida, desenvolvendo-se inicialmente 
assintomaticamente no fígado, onde milhares de merozoítos, a forma do parasita capaz de infectar 
eritrócitos, são originados. Uma vez libertados na corrente sanguínea, os merozoítos rapidamente 
infectam eritrócitos, dando origem a mais merozoítos, e iniciando a fase eritrocitária do seu ciclo de 
vida e sintomática da doença. Contudo, ao fim de alguns ciclos de multiplicação em eritrócitos, alguns 
merozoítos acabam por gerar gametócitos, as formas sexuais do parasita, que são ingeridas pelo 
mosquito aquando da sua refeição de sangue. No mosquito, os gametócitos dão início à fase 
sexuada do ciclo de vida do parasita, que culmina com a formação de esporozoítos capazes de 
infectar novos hospedeiros mamíferos.  
Durante décadas, muitos esforços têm sido empregues com o intuito de erradicar a malária. 
Contudo, estes têm-se revelado infrutíferos, e tanto parasitas como mosquitos resistentes às medidas 
de controlo empregues têm emergido nos últimos anos. Perante este cenário, tem-se sugerido que o 
desenvolvimento de terapias capazes de bloquear a transmissão do parasita do Homem para o 
mosquito, nomeadamente o de uma vacina eficaz contra a malária, é urgentemente necessário e 
crucial para se alcançar a erradicação da doença. 
Há muito que se tenta desenvolver uma vacina anti-malárica eficaz. No entanto, tal tem-se 
revelado um dos maiores desafios da medicina, principalmente devido à extraordinária complexidade 
do ciclo de vida do parasita, durante o qual este se desenvolve e diferencia em formas que 
apresentam uma morfologia, metabolismo e conteúdo antigénico completamente distintos consoante 
a fase em que o parasita se encontra. A fase hepática constitui um alvo ideal para o desenvolvimento 
de uma vacina, uma vez que o desenvolvimento de uma vacina pré-eritrocitária eficaz teria 
simultaneamente capacidade profiláctica e de bloqueio da transmissão: a eliminação das formas pré-
eritrocitárias do parasita (o esporozoíto e a forma exo-eritrocitária em desenvolvimento – EEF - dentro 
dos hepatócitos), permitiria impedir o aparecimento dos sintomas da infecção e, consequentemente, a 
transmissão do parasita ao mosquito. Contudo, uma vacina pré-eritrocitária tem que ser 100% eficaz 
em eliminar o parasita: basta que um esporozoíto se desenvolva completamente no fígado para que 
ocorra doença e, consequentemente, transmissão. 
Vários estudos demonstram que a administração de esporozoítos atenuados mas 
metabolicamente activos é capaz de induzir uma resposta imune eficiente de longa duração em 
ratinhos, macacos e humanos, contra futuras infecções por esporozoítos. De facto, a desilusão 
relativa à eficácia de vacinas baseadas apenas em partes recombinantes de antigénios do parasita, 
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tem despertado um grande interesse para o desenvolvimento de uma vacina usando esporozoítos 
vivos atenuados que, em última análise, constitui uma vacina multi-antigénica e em tudo semelhante 
ao parasita infeccioso. 
Os esporozoítos podem ser eficientemente atenuados através da sua exposição a uma 
determinada dose específica de radiação ionizante (X ou γ) (radiation attenuated sporozoites - RAS), 
ou da sua manipulação genética, em que genes essenciais para o desenvolvimento das formas pré-
eritrocitárias do parasita são danificados (genetically attenuated sporozoites - GAS). Em ambas as 
estratégias de atenuação, os esporozoítos atenuados mantêm a sua capacidade de invadir 
hepatócitos, tal como o parasita selvagem, mas demonstram uma grave deficiência no seu 
desenvolvimento uma vez dentro da célula hospedeira, que os impede de produzir merozoítos e 
assim, causar doença. Esta deficiência em completar o seu desenvolvimento dentro do hepatócito 
tem sido associada com a incapacidade que os parasitas atenuados têm de inibir a apoptose da 
célula hospedeira.  
Ao longo da evolução, os microrganismos intracelulares desenvolveram mecanismos que lhes 
permitem manipular os processos biológicos da célula hospedeira para seu benefício. Um dos 
processos que mais pressão selectiva tem imposto aos microrganismos intracelulares tem sido a 
morte das células hospedeiras por apoptose. Apesar de a apoptose poder ser desencadeada através 
de diversos estímulos e vias de sinalização, a via extrínseca, accionada por ligandos extracelulares, e 
a via intrínseca, desencadeada por sinais internos como o stress, são as mais comuns em células de 
mamíferos. Embora sejam despoletadas por diferentes estímulos, as duas vias apoptóticas 
convergem na activação de efectores comuns, as proteínas caspase, nomeadamente a da caspase-
3, que aquando da sua activação, leva em última instância à morte celular e à resultante formação de 
corpos apoptóticos. Tal como em outros microrganismos intracelulares, tem sido demonstrado que os 
estádios pré-eritrocitários de Plasmodium possuem a capacidade de inibir a apoptose dos hepatócitos 
infectados, tanto aquando do processo de invasão, como durante os estádios iniciais e tardios do seu 
desenvolvimento. Aparentemente, a protecção da célula hospedeira à apoptose durante o 
desenvolvimento do parasita requer que este se mantenha vivo, e possivelmente, em processo de 
desenvolvimento. Várias observações sugerem que os parasitas atenuados, tanto RAS como GAS, 
são incapazes de evitar que a célula infectada entre em processo de apoptose e que, de facto, a 
imunidade gerada aquando da imunização com os parasitas atenuados resulta da sua incapacidade 
em proteger a célula hospedeira de entrar em apoptose aquando da infecção.  
Quando a célula infectada sofre apoptose, formam-se corpos apoptóticos carregados com 
antigénios celulares e do parasita. Estes podem depois ser fagocitados por células apresentadoras de 
antigénios, tais como macrófagos e células dendríticas. Posteriormente, estas células podem fazer a 
apresentação destes antigénios ao sistema imunitário, desencadeando respostas imunes específicas 
contra o parasita. Vários estudos têm associado as células dendríticas com o estabelecimento da 
imunidade protectora induzida pelos parasitas atenuados, apontando-as como o veículo entre as 
células infectadas em apoptose e o sistema imunitário. De facto, as células dendríticas encontram-se 
associadas com a apresentação de antigénios exógenos através de moléculas de 
histocompatibilidade de classe I a células T CD8+, os principais elementos da resposta imune celular 
gerada pelos parasitas atenuados. 
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O presente trabalho pretende testar a hipótese de que a apoptose das células infectadas com os 
parasitas atenuados se encontra intimamente relacionada com o estabelecimento bem sucedido da 
resposta imune gerada por estes parasitas contra posteriores infecções por esporozoítos infecciosos.  
Recorrendo a ratinhos da linhagem C57BL/6 deficientes em caspase-3 (Casp3KO), um elemento-
chave em diversas vias da apoptose, vários ensaios de imunização com parasitas P. berghei ANKA 
atenuados, quer por a radiação γ (Pb-RAS), ou por manipulação genética (Pbp36p-), foram 
realizados. Em cada ensaio, a posterior infecção foi efectuada com esporozoítos P. berghei ANKA 
que expressam constitutivamente a proteína de fluorescência verde (PbGFP) ou luciferase (PbLuci). 
Estes parasitas permitem, respectivamente através da análise por PCR quantitativo em tempo real 
(qRT-PCR) ou imagiologia in vivo em tempo real, inferir o nível de infecção no fígado e assim, a 
eficiência do regime de imunização. Contudo, o estabelecimento de uma resposta imunitária 
completamente eficiente contra a infecção foi apenas irrefutavelmente depreendida através da 
vigilância e seguimento do aparecimento de parasitas no sangue dos animais. Estes ensaios 
permitiram-nos verificar que os ratinhos Casp3KO encontram-se apenas parcialmente protegidos 
contra a infecção com esporozoítos infecciosos, sugerindo que as vias apoptóticas dependentes de 
caspase-3 se encontram possivelmente envolvidas no estabelecimento da imunidade induzida pelos 
parasitas atenuados.  
De modo a excluir a possibilidade de que a imunidade parcial observada nos ratinhos Casp3KO se 
deve a uma deficiência ao nível do sistema imunitário destes animais, uma vez que se pensa dever à 
diminuição do nível de apoptose das células infectadas no fígado, a medula óssea de ratinhos 
Casp3KO foi substituída pela de ratinhos C57BL/6 normais, e vice-versa. Os ratinhos quimera 
resultantes foram imunizados com Pb-RAS, e posteriormente infectados com PbLuci. Infelizmente, 
este ensaio não nos permitiu retirar quaisquer conclusões concretas, apesar de sugerir que o fenótipo 
observado nos ratinhos Casp3KO imunizados se deve à sua maior resistência à apoptose nas células 
hepáticas infectadas com os parasitas atenuados. 
Através de uma sonda fluorescente que permite detectar níveis de apoptose in vivo, foi-nos 
possível inferir que há um aumento do nível de apoptose no fígado de ratinhos C57BL/6 infectados 
com PbRAS, que é aparentemente superior ao observado em ratinhos Casp3KO infectados com os 
mesmos parasitas, e ratinhos C57BL/6 infectados com parasitas infecciosos. Estes resultados 
permitem-nos de certo modo confirmar as observações de que os parasitas atenuados por radiação 
são incapazes de proteger a célula hospedeira de sofrer apoptose. 
Em conjunto, os resultados aqui apresentados aparentam suportar a hipótese proposta, de que a 
apoptose das células infectadas com parasitas atenuados é relevante para o estabelecimento da 
resposta imune efectiva induzida por estes. Perante este panorama, planeámos construir um parasita 
P. berghei ANKA transgénico que expressa e exporta para o citoplasma das células hospedeiras 
caspase-2, um factor pró-apoptótico, com o intuito de induzir a apoptose das células infectadas e 
inferir se a infecção de ratinhos com este parasita é capaz de induzir uma resposta imune eficaz 
contra infecções posteriores com esporozoítos infecciosos P. berghei ANKA. 
Palavras-chave: Malária, Parasitas Atenuados, Apoptose da célula hospedeira, Imunidade.  
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MOST USED ABBREVIATIONS 
BS – Blocking Solution. 
Casp3KO mice - C57BL/6 background caspase-3 
deficient mice. 
CD8+ TCM – central memory CD8+ T cells. 
CD8+ TEM – effector memory CD8+ T cells. 
ChimC57BL/6 – C57BL/6 mice reconstituted with 
Casp3KO mice bone marrow. 
ChimCasp3KO - Casp3KO mice reconstituted with 
C57BL/6 mice bone marrow. 
CM – cerebral malaria. 
CSP – circumsporozoite protein. 
DC – Dendritic Cell. 
EEF – Exoerythrocytic form. 
ELISA – enzyme-linked immunosorbent assay. 
ELISPOT – enzyme-linked immunosorbent spot assay. 
GAS – Genetically Attenuated Sporozoites. 
i.p. – Intra-peritoneal.  
i.v. – intravenously. 
ImmC57BL/6 – group of C57BL/6 mice that were 
immunized, either with PbRAS or PbP36p- sporozoites, 
and subsequently infected (challenged) with WT PbGFP 
sporozoites.  
ImmCasp3KO – group of Casp3KO mice that were 
immunized, either with PbRAS or PbP36p- sporozoites, 
and subsequently infected (challenged) with WT PbGFP 
sporozoites.  
InfC57BL/6 – group of C57BL/6 mice that were only 
infected. 
InfCasp3KO – group of Casp3KO mice that were only 
infected. 
Inf-IrrC57BL/6 – C57BL/6 mice infected with PbGFP-RAS. 
Inf-IrrCasp3KO – Casp3KO mice infected with PbGFP-
RAS. 
N.I.C57BL/6 – non-infected C57BL/6 mice. 
NIrr – Non-irradiated. 
p.i. – post infection. 
PbGFP – green fluorescent protein (GFP) – expressing P. 
berghei ANKA. 
PbGFP-Irr Hosp – PbGFP parasites that were exposed to 
a γ-radiation dose of 16 Krad in a Compagnie Oris 
Industrie IBL 437C irradiator. 
PbGFP-Irr IMM – PbGFP parasites that were exposed to a 
γ-radiation dose of 16 Krad in a MDS Gamma Cell 3000 
Elan irradiator.  
PbGFP-RAS – Radiation attenuated PbGFP sporozoites. 
PbLuci – luciferase – expressing P. berghei ANKA. 
Pbp36p- - P36p deficient GFP – expressing Plasmodium 
berghei ANKA. 
PbRAS – Plasmodium berghei radiation attenuated 
sporozoites.  
PV and PVM – parasitophorous vacuole and 
parasitophorous vacuole membrane. 
qRT-PCR - Quantitative Real-Time Reverse Transcription 
PCR. 
RAS – Radiation Attenuated Sporozoites. 
RBM – Roll Back Malaria partnership. 
RT – Room temperature. 
WHO – World Health Organization. 
WT – Wild Type. 
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INTRODUCTION 
MALARIA 
Malaria is a disease that, despite all the efforts towards its eradication, and all the scientific 
breakthroughs, remains, in the 21st century, the world’s most deadly and morbid parasitic and vector-
borne infectious disease. Presently, malaria is a life-threatening risk for 3,3 billion people over 109 
countries, in the African, Asian and South American continents (Figure 1.). In 2008 alone, it was 
responsible for as many as 243 million cases of disease and 863.000 deaths, 85% of the losses being 
African children under the age of 5 (WHO, 2009). Moreover, malaria has an overwhelming impact on 
the affected countries’ economy, being annually accountable for a decrease in the gross domestic 
product (GDP) of as much as 1.3% in countries with high levels of transmission, and has consequently 
lead to economical and social disparities between countries with and without malaria (WHO, 2010).  
Malaria is caused by protozoan parasites from the Plasmodium genus, and a member of the 
Apicomplexa phylum, to which other human pathogens, such as Toxoplasma gondii and 
Cryptosporidium parvum, also belong (Ejigiri and Sinnis, 2009). By 2008 there were 199 Plasmodium 
described species that, as a group, are able to infect a broad range of vertebrate hosts such as 
mammals, birds, and squamat reptiles (Martinsen et al., 2008), although each Plasmodium species 
has a remarkably restricted host range, and typically only infects few closely related vertebrate 
species (Matuschewski, 2006). In humans, malaria is mainly caused by four Plasmodium species, P. 
falciparum, P. vivax, P. ovale and P. malariae, although a fifth species, P. knowlesi, a natural parasite 
of macaque monkeys in south-east Asia, has been recently described to have occasionally infected 
and caused disease in humans (WHO, 2010). Together with P. vivax, P. falciparum, which is 
responsible for most of the severe and deadly malaria cases, accounts for the vast majority (over 
93%) of the clinical cases notified each year (WHO, 2009), while P. ovale and P. malariae contribute 
to a lesser number of malaria infections (RBM, 2008). Malaria is transmitted to the vertebrate host by 
the bite of infected female mosquitoes, members of genera that comprise the most ubiquitous and 
Figure 1. Global map of malaria-free countries and malaria-endemic countries in phases of control, pre-elimination, 
elimination and prevention of reintroduction by the end of 2008 (WHO, 2009).  
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abundant arthropod populations in most parts of the world: Anopheles in the case of mammalian 
malaria, and both Culex or Aedes in the case of avian malaria (Matuschewski, 2006). In fact, the use 
of such vectors constitutes one of the main reasons for malaria’s success.  
Plasmodium LIFE CYCLE 
Plasmodium parasites possess a complex life cycle, divided into two obligatory hosts where 
asexual, in the vertebrate, and sexual, in the mosquito, stages take place. During both, the parasite 
follows a developmental programme where it changes from extracellular motile invasive stages, to 
intracellular replicative ones (Matuschewski, 2006).  
While taking its blood meal from a mammal host, the infected female Anopheles mosquito deposits 
sporozoites, a parasite infective form that is unable to infect erythrocytes, into the host avascular 
dermal tissue (Amino et al., 2006) (Figure 2. A). Here, sporozoites persist for some time, 1-3 hours 
(Amino et al., 2006; Yamaushi et al., 2007), apparently moving in a random fashion by gliding motility, 
an active movement pattern characteristic of Plasmodium spp. This is accompanied by active 
migration through the host cells with membrane disruption, and is required for sporozoite exit from the 
dermis. Migration, by traversing cells, allows the sporozoites to penetrate cell barriers, to escape 
destruction by phagocytic cells in the dermis, and to reach successfully the bloodstream (Amino et al., 
2008). However, only a proportion of the initially inoculated sporozoites leaves the dermis, penetrates 
a blood vessel, and is carried within the bloodstream. Some sporozoites remain in the dermis, where 
they are probably eliminated by recruited phagocytes, while others penetrate a lymphatic vessel and 
reach the lymph node. Here, sporozoites are either phagocytosed by dendritic cells (DCs) or partially 
develop into early small exoerythrocytic forms (EEFs), before being degraded (Amino et al., 2006). 
Once in the bloodstream, sporozoites rapidly home to the liver, starting an obligatory and clinically 
silent liver, or pre-erythrocytic, stage of infection that, in humans, can last for 6 to 40 days, depending 
on the Plasmodium species (Murray et al., 2005). In the liver, sporozoites glide freely along the 
sinusoidal epithelium until they get sequestered. Here, they invade Kupffer cells, the liver’s resident 
macrophages, and gain access to the liver parenchyma (Frevert et al., 2005) (Figure 2. B). 
Sporozoites then migrate through several hepatocytes, before productively invading a single final one 
with the formation of a parasitophorous vacuole (PV) (Mota et al., 2001) (Figure 2. C). Afterwards, 
each invasive sporozoite dedifferentiates and develops into an EEF that grows and increases 
dramatically in volume without annihilating the host cell (reviewed in Vaughan et al., 2008) (Figure 2. 
D). During its growth, the EEF multiplies by schizogony (a process in which karyokinesis is temporally 
separated from cytokinesis, and a hallmark of Plasmodium spp. replication stages; Aly et al., 2009) 
into thousands of merozoites, the parasite’s next infective form capable to infect erythrocytes, that stay 
enclosed within the PV membrane (PVM) (Sturm et al., 2006). When EEF development is completed, 
merozoites are released from the PVM freely in the host cell cytoplasm, after which merozoite-filled 
vesicles from host cell membrane origin, the merosomes, are formed and released into the liver 
sinusoid (Sturm et al., 2006) (Figure 2. E).  
Once in the liver sinusoids, the merosomes enter the bloodstream and accumulate in the lung’s 
microvasculature, where they finally break up releasing merozoites into the bloodstream (Baer et al., 
2007; Strum et al., 2006) (Figure 2. F), and starting the symptomatic blood, or erythrocytic, stage of 
infection. Merozoites then rapidly attach to the erythrocytes, further penetrating them with the 
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formation of a PV. Subsequently, the invasive merozoite converts into a ring stage form, which 
develops into a trophozoite stage. The trophozoite then starts to multiply by schizogony, transforming 
itself into an erythrocyte schizont stage, which ultimately originates newly formed merozoites. When 
fully developed, merozoites egress from the erythrocyte, by PV and erythrocyte membrane rupture, 
after which they rapidly infect other erythrocytes, initiating a new erythrocytic cycle (reviewed in Silvie 
et al., 2008) (Figure 2. F). It is when the erythrocytes release merozoites that the typical pattern of 
malaria symptoms appears: the paroxysms, consisting of chills, high fever and malarial rigors (Murray 
et al., 2005). These usually appear periodically, the time interval depending on the length of the 
Plasmodium species erythrocytic cycle (in humans can be of 24-72 hours), and may remain relatively 
mild, or progress to severe attacks with hours of sweating, chills, persistent high fever and exhaustion 
(Murray et al., 2005). If not treated, P. falciparum malaria evolves to a severe, and maybe fatal, 
disease with involvement of the brain, cerebral malaria, due to the accumulation of parasitized cells 
and cellular debris. After several erythrocytic cycles, some merozoites give origin to the sexual stages, 
the male and female gametocytes (Figure 2. G).  
When a mosquito takes its blood meal from an infected individual, gametocytes are ingested, 
starting the sexual part of the parasite’s life cycle (Figure 2. H). Here, the midgut lumen environment 
triggers gametocytes to rapidly undergo gametogenesis (Bilker et al., 1997; Bilker et al., 1998), 
originating the male and female gametes that subsequently fuse to form the zygote, the only diploid 
form during the parasite’s life cycle. Soon after its formation, the zygote endures meiosis and genetic 
recombination, converting itself into an ookinete, a motile form of the parasite. Thereafter, the ookinete 
breaches the peritrophic matrix that encloses the blood meal and penetrates the mosquito midgut 
epithelium, where it traverses several epithelial cells. Subsequently, it exits the epithelium, and 
initiates its transformation into a sessile oocyst, the only extracellular developmental stage of the 
Figure 2. Plasmodium spp. life cycle. Detailed description in the text. (A) The infected mosquito deposits sporozoites in the 
host’s skin where they gain access to a blood vessel. (B) In the liver sinusoids, sporozoites invade Kupffer cells and get access 
to the liver parenchyma. (C) Sporozoites migrate through several hepatocytes, invading a final one with formation of a PV. (D) 
Sporozoites then develop into EEFs, giving rise to thousands of merozoites. (E) Merosomes are release from the infected 
hepatocyte into the sinusoid lumen. (F) Erythrocytic cycle. (G) Some merozoites originate the male and female gametocytes. (H) 
During a blood meal, the mosquito uptakes the gametocytes, starting the parasite’s sexual part of the life cycle that ends with 
the accumulation of thousands of sporozoites in the salivary glands. (I) The mosquito takes a blood meal, and the cycle restarts. 
Adapted from Plasmodium life cycle from Malaria Unit of IMM. 
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parasite (reviewed in Aly et al., 2009). Afterwards, the oocyst develops, undergoing several mitotic 
divisions to originate sporoblasts, from which sporozoites start budding. When fully developed, 
thousands of mature sporozoites actively egress the oocyst and enter the hemocoel, where are 
carried through all mosquito tissues by the circulatory system, the hemolymph. While passing through 
the salivary glands, sporozoites adhere to the basal lamina, breach it, and invade the salivary gland 
secretory acinar cells, getting access to the salivary duct, where they accumulate and finish their 
maturation (reviewed in Aly et al., 2009). When the mosquito takes its next blood meal, sporozoites 
are injected into the mammalian host, starting the asexual part of the parasite’s life cycle (Figure 2. I). 
MALARIA ERADICATION EFFORTS AND CONTROL MEASURES 
Throughout time, many have been the efforts to control, eliminate and, ultimately, eradicate 
malaria. However, these have not been completely successful, although malaria elimination was 
effectively achieved in Europe, North America and some countries in the North of Africa (Figure 1.). In 
1959, the World Health Organization (WHO) launched the first attempt to eradicate malaria, the Global 
Programme for Malaria Eradication, which was based on mosquito control through indoor residual 
spraying (IRS) with dichloro-diphenyl-trichloroethane (DDT), and treatment of the infected populations 
with chloroquine (Greenwood, 2009). Sadly, the ambitious programme did not succeed in its main 
goal, and was abandoned in 1969. Nevertheless, it allowed malaria elimination in over 30 countries, a 
decrease of clinical burden in several endemic countries outside the African continent, and the 
removal of malaria risk from over one billion people (Greenwood, 2008; Greenwood, 2009). After the 
programme was abandoned, for some time no other attempts were made to eradicate malaria, and the 
efforts were directed to regional control and elimination, as has been done previously to the 
programme for years, back then, with limited success (Greenwood, 2009). In 2007, the Melinda and 
Bill Gates Foundation, the WHO, and the Roll Back Malaria Partnership (RBM) joint efforts to 
accomplish malaria eradication. This time, eradication will be endorsed by promoting national and 
regional gradual elimination using combinations of tools that are currently available: the artemisinin 
combination therapies (ACTs), the chemoprophylaxis or intermittent preventive treatment (IPT), IRS, 
and insecticide–treated bed nets (ITNs) or long-lasting ITNs (LLITNs) (Greenwood, 2008; Greenwood, 
2009). It is believed that in many epidemiological situations the correct widespread and combination of 
these tools will be able to achieve up to 90% reduction in malaria clinical burden regionally. However, 
it is doubtful that in medium or high transmission areas these will be enough to accomplish malaria 
elimination and ultimately, eradication (Greenwood and Targett, 2009). Moreover, the emergence of 
resistance against several antimalarials by the parasite, and against several insecticides by the 
mosquito, threaten their efficacy. Therefore, it is argued that tools efficient in blocking parasite 
transmission, such as new gametocytocidal drugs, safer than primaquine, along with an efficient 
antimalarial vaccine, are essential and crucial for ultimate malaria eradication (reviewed in 
Greenwood, 2008). 
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MALARIA VACCINATION STRATEGIES 
Since the early 19th century, researchers have struggled to develop an effective antimalarial 
vaccine, long acknowledged as one of the greatest challenges of medicine (Luke and Hoffman, 2003). 
The main reason for this fruitless quest relies on the complexity of the parasite’s life cycle, comprising 
three distinct stages, each with a different gene expression pattern and consequently, different 
morphology, metabolism and antigen content (Vaughan et al., 2010). The pre-erythrocytic stages of 
the parasite, the sporozoite and the developing EEF, constitute attractive targets for vaccine 
development: they are present in lower numbers than the erythrocytic stages, are completely 
asymptomatic, and provide a relatively large window of opportunity for an effective immune response 
to eliminate the parasite (Vaughan et al., 2010), given that parasite development in the human liver 
lasts for several days. Moreover, pre-erythrocytic stages appear to not exhibit substantial antigenic 
variation or antigenic polymorphisms (Vaughan et al., 2010), conferring to a pre-erythrocytic vaccine 
the potential of being effective against heterologous parasite strains. If completely efficient, a pre-
erythrocytic vaccine would promote the elimination of the parasite in the liver, therefore preventing 
disease onset, and consequently, parasite transmission. In fact, the major challenge for a successful 
pre-erythrocytic vaccine is that it is an all-or-none vaccination strategy, as it must eliminate every 
single parasite in the liver because, if even just one is able to fully develop, the parasite will proceed to 
the blood, cause disease and consequently, be transmitted (Vaughan et al., 2010).  
The development of an effective pre-erythrocytic vaccine has relied mainly on two strategies, the 
subunit and the live attenuated whole organism approaches.  
THE SUBUNIT VACCINE APPROACH 
Most of the efforts to develop an effective vaccine against malaria have focused on the 
recombinant subunit approach. Several vaccine candidates have emerged through time, but the 
majority proved to be inefficient in inducing protective immunity in humans and were early abandoned. 
However, two strong candidates have reached human clinical trialsa
Sf66 was the first vaccine candidate to incorporate peptide sequences derived from both pre- and 
erythrocytic stages of the parasite life cycle. Sf66 was based on a synthetic peptide unit that, besides 
comprising the immunodominant unit NANP (N, asparagines; A, alanine; P, proline) of the CSP, also 
incorporated a fragment of the merozoite surface protein 1 (PfMSP-1, involved in the merozoite initial 
attachment to the erythrocyte upon infection) (reviewed in Silvie et al., 2008), and two uncharacterized 
peptides of 55 and 35KDa (Snounou and Rénia, 2007). Initially, Sf66 showed strong evidence of 
conferring protection against P. falciparum blood-stage challenge in monkeys and human volunteers. 
Facing such results, Sf66 was further tested, between 1992 and 1999, in several independent clinical 
, the Sf66 and the RTS,S 
vaccines, both comprising parts of the P. falciparum circumsporozoite protein (CSP), which is only 
expressed in the pre-erythrocytic stages of the parasite, both in the sporozoite and the EEF 
(Greenwood and Targett, 2009).  
                                                            
a Steps in malaria vaccine development. (1) Research and preclinical development – identification of antigens and creation 
of the vaccine concept, preclinical evaluation in animal models and development of the manufacturing process. (2) Phase I 
Clinical Trials (CT) – safety profile and immune response preliminary evaluation in naïve and exposed populations. (3) Phase 
II CT – safety and potential side effects monitoring, immune response measurement, efficacy against infection and clinical 
disease evaluation and determination of the optimum dosage and schedule. (4) Phase III CT – further safety and potential side 
effects monitoring and efficacy evaluation on a large scale. (5) Submission to regulatory authorities. (6) Introduction in the 
market. (7) Phase IV CT – post-marketing safety monitoring, protection duration measurement and vaccine compliance 
assessment. (adapted from GSK, 2010) 
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trials in endemic countries. Unfortunately, it showed a reduced efficacy against infection, and was 
abandoned after being considered of no use in malaria control (Snounou and Rénia, 2007).  
The RTS,S vaccine is the most clinically advanced antimalarial vaccine candidate so far. It is based 
on the hepatitis B surface antigen (HBsAg or S antigen) virus-like particle platform, genetically 
engineered to harbour a P. falciparum CSP construct comprising 19 NANP repeats of the protein 
central region, known to induce B cell responses, and its entire C-terminal flanking region, known to 
induce specific T cell responses (Casares et al., 2010). To enhance its immunogenicity, the RTS,S 
construct was formulated in association with several adjuvant systems (AS), shown to induce strong 
humoral and cellular immune responses. Two formulations, RTS,S/AS02 and RTS,S/AS01 have 
shown promise results in studies with human volunteers, and were further tested in phase II clinical 
trials in endemic countries (GSK, 2010). In these clinical trials both formulas were shown to be safe to 
use as a vaccine in young children, with a strain unspecific efficacy against infection of about 45%, 
sadly far from ideal. Unexpectedly, since RTS,S was designed to act on pre-erythrocytic stages by 
only incorporating CSP as an immunogen, RTS,S formulations have also shown to be effective 
against clinical malaria, with around 44% efficacy, and against severe malaria development, with 
nearly 49% efficacy (Vekemans et al, 2009; Casares et al., 2010). Unfortunately, the efficiency of both 
formulas tended to decline with time. Altogether, RTS,S/AS01 showed a higher efficiency and more 
favourable safety data than RTS,S/AS02, and was selected for further evaluation in a phase III pre-
licensure pivotal efficiency trial in several endemic countries, meaning that, a partially effective 
antimalarial vaccine will, hopefully, be available in a near future (Vekemans et al, 2009). Nonetheless, 
giving that the RTS,S has an efficacy lower that 50% against infection,  it is arguable whether RTS,S 
will be useful when added to the other control measures in the quest to eradicate malaria (90% with 
the current tolls compared to 93% when combined with the vaccine). Moreover, the fact that it is only 
based on one P. falciparum protein raises the concern of whether a single protein based vaccine will 
be adequate to sustain malaria control, especially because it may bear the risk of emergence of 
resistant parasites (Greenwood and Targett, 2009; Luke and Hoffman, 2003). 
THE LIVE ATTENUATED WHOLE ORGANISM VACCINE APPROACH – RAS & GAS 
The observation that subunit vaccines fail to provide any significant and long lasting protective 
immunity has stimulated recent attempts to produce a vaccine based on an alternative approach, in 
which non-replicating but metabolically active live attenuated whole organisms are used. In fact, 
attenuated whole organism vaccines represent 75% of the currently licensed anti-viral and anti-
bacterial vaccines (Good, 2005), as it is the case of the ones against poliovirus, measles, typhoid 
fever, and tuberculosis (reviewed in Hoffman et al., 2010). Throughout the years, it has been shown 
that this approach can, at least in theory, be applied to the development of a highly effective 
antimalarial vaccine.  
In 1967, it was demonstrated that immunization of mice with P. berghei, a rodent malaria parasite, 
radiation-attenuated sporozoites (RAS) was able to completely abrogate the onset of blood stage 
infection after challenge with infectious P. berghei sporozoites (100% efficacy) (Nussenzweig et al., 
1967). Subsequently, the same level of sterile protection against infection was also induced in 
monkeys (Collins and Contacos, 1972) and humans (Clyde et al., 1973), immunized with P. cynomolgi 
RAS and P. falciparum RAS, respectively. Moreover, the protection conferred by immunizations with 
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RAS was shown to be long-lasting either in mice, monkeys or humans (Nussenzweig et al., 1967; 
Clyde et al., 1973; Hoffman et al., 2002). Soon, it became evident that the safety and efficacy of the 
RAS parasites relied on a precise and adequate radiation dose (ionizing radiation, either X- or γ- 
radiation). The proper irradiation of the sporozoites introduces random mutations and breaks into the  
DNA, to an extent that allows them to survive and keep their ability to successfully invade 
hepatocytes, although their capacity to fully develop is completely abrogated, and therefore, infection 
with these RAS does not cause disease and parasite transmission (Figure 3. B) (Vaughan et al., 
2010). Conversely, under-irradiation of sporozoites allows them to remain infectious and to fully 
mature in the liver, therefore causing malaria, while over-irradiation completely inactivates or kills the 
sporozoites, that consequently are not able to infect hepatocytes (Vanderberg et al., 1968). In fact, 
over-irradiated sporozoites fail to confer any significant protection, suggesting that antigens expressed 
by persistent, partially developed liver stage parasites may be critical for the induction and 
maintenance of protective immunity, thereby indicating that RAS must invade liver cells and persist as 
at least partially developed EEFs to induce an immune response (Ballou, 2007). Because RAS 
comprehend the entire parasite, they act as a complete multi-antigen vaccine, possessing all the 
antigens of the infective non-irradiated sporozoites (N-Irr). Therefore, the resulting immune response 
is quite complex, involving both cellular and humoral immune responses against infected hepatocytes 
and surface antigens present in the sporozoite surface, like the CSP (reviewed in Ballou, 2007).  
Despite all the promising results of obtaining 90-100% efficacy of protection against infection in 
humans with RAS (Hoffman et al., 2002), for decades it was considered impossible to develop, license 
and commercialize a live attenuated whole organism vaccine for P. falciparum (Ballou, 2007). The 
main obstacles to its development were mainly associated with the processes of producing, collecting 
and purifying the sporozoites, which present a high risk of contamination with other potentially 
Figure 3. The fate of wild-type and attenuated parasites 
once in the mouse liver. (A) Normal infection by a wild type 
sporozoite. (B) Infection by RAS. (C) Infection by GAS. (B) 
and (C) both successfully home to the liver and infect 
hepatocytes, but do not fully develop to generate merozoites. 
(D) Different levels of parasite development inside the 
hepatocyte by several GAS. Adapted from Waters et al., 
2005, and Vaughan et al., 2010. 
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pathogenic transmissible agents, from both human and mosquito origin, as well as with allergenic 
mosquito proteins. These concerns come from the fact that sporozoite production involves feeding the 
mosquitoes with gametocyte-infected human blood (always considered to carry an inherent non-zero 
risk of infectious agents), and further sporozoite collection and purification, involving the removal and 
disruption of the mosquito’s salivary glands. Moreover, the capability of scaling up these processes 
has also been a great limiting factor, as well as how this type of vaccine would be preserved and taken 
to the endemic areas (Ballou, 2007). In 2003, Stephen Hoffman, founder of the Sanaria Inc., and co-
workers reappraised the potential of an attenuated whole organism vaccine against malaria, as well as 
the obstacles to produce it, and took the challenge to develop such a vaccine (Luke and Hoffman, 
2003). Presently, Sanaria Inc. possesses the world’s first licensed facility for manufacturing a live 
attenuated malaria vaccine, where an entire single coordinated process of producing and preserving 
the first generation attenuated whole organism vaccine against P. falciparum malaria, the SanariaTM 
PfSPZ vaccine, has been developed (Hoffman et al., 2010). This tightly controlled process has 
enabled Sanaria Inc. to overcome the risks and limitations of contaminations, improper radiation of the 
sporozoites, as well as their further preservation and delivery to endemic countries, by 
cryopreservation, storage and distribution of the RAS in liquid nitrogen vapor phase (LNVP), an 
electricity-independent platform (Hoffman et al., 2010). Currently, the SanariaTM PfSPZ vaccine, given 
by intradermal (ID) or subcutaneous inoculation (SC) is being tested in phase I clinical trials, in 
experimentally challenged malaria naïve volunteers to assess its safety, immunogenicity, adequate 
dose, and protective efficacy (Vaughan et al., 2010). Ultimately, during clinical trials SanariaTM PfSPZ 
must demonstrate that it is aseptic (free from contaminating pathogens), pure (free of contaminating 
mosquito material), non-replicating (arrests during EEF development and is thus unable to cause 
malaria), and potent (capable of inducing protective immune response), in order to be introduced in 
the market (Hoffman et al., 2010). If it develops favourably, after all these years of research, an 
attenuated whole organism vaccine against malaria, with a high efficacy of protection, may finally be 
available in a relatively near future, and become an important tool to achieve malaria eradication. 
Although the efforts and breakthroughs accomplished by Sanaria Inc. appear to finally make 
feasible the development of a live attenuated whole organism vaccine using RAS, there will always be 
reservations regarding the safety and reproducibility of the radiation process (Ballou, 2007), as it is 
unacceptable that a vaccine itself may cause disease if it is improperly attenuated. Fortunately, 
advances in genetic engineering may have allowed researchers to overcome this problem. The 
availability of genome sequences for a number of Plasmodium species, including of P. falciparum, the 
generation of stage-specific gene expression data, and the capacity to genetically manipulate the 
parasite, has allowed the search for essential genes involved in parasite survival at different stages of 
its life cycle. Together, these have enabled the informed genetic manipulation of the parasite to 
produce genetically-attenuated sporozoites (GAS), that can be designed to exhibit distinct biological 
and antigenic features, therefore allowing the creation of strains that are safe and elicit complete 
protection, with low dose immunizations (Vaughan et al., 2010).  
It has been demonstrated that the gain of infectivity by sporozoites (from non-infective sporozoites 
in the midgut to infective sporozoites inside the salivary glands) is accompanied by an extensive 
differential upregulated expression of the upregulated in infectious sporozoites (UIS) genes 
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(Matuschewski et al., 2002). Disruption of several of UIS genes, which the parasite lacks the ability to 
compensate for their loss, has been done in rodent parasites like P. berghei and P. yoelii, and allowed 
researchers to test whether it is feasible to develop an efficient genetically-attenuated antimalarial 
vaccine. In P. berghei, disruption of the UIS3 and UIS4 genes, both encoding transmembrane proteins 
present in the EEF PVM, as well as of the P36p gene (also termed P52), encoding for a putative 
glycosylphosphatidylinositol (GPI)-anchored protein, member of the 6-Cys domain protein family, has 
been successfully achieved by double cross-over recombination gene replacement. The resulting 
parasites, uis3-, uis4- and p36p-, have revealed complete arrest in EEF development soon after 
hepatocyte invasion (Figure 3. D), although all three have shown, as expected, to present a 
phenotype comparable to the one of the wild type (WT) parasite regarding the blood stage and 
mosquito stage infections, as well as hepatocyte migration and invasion processes (Mueller et al., 
2005a; Mueller et al., 2005b; van Djik et al., 2005). However, in the case of the p36p- parasites, a 
consensus regarding the later processes has not been established. In two independent studies where 
p36p- parasites were generated using similar strategies, one reported an increase in migration and a 
decrease in invasion with PV formation (Ishino et al., 2005), while the other described that both 
processes are comparable to those of the WT parasite, although invasion occurred without the 
formation of a PV (van Djik et al., 2005). Nevertheless, when mice were immunized with uis3-, uis4- or 
p36p- parasites, complete and long-lasting immunity was generated against further challenges with 
WT sporozoites (Mueller et al., 2005a; Mueller et al., 2005b; Ishino et al., 2005; van Djik et al., 2005), 
demonstrating that rodent model GAS are highly effective vaccines. Unfortunately, when given to mice 
in high doses, uis4- and p36p- parasites (from both studies) were reported to cause breakthrough 
infections, although with a delayed appearance of parasites in the blood (Mueller et al., 2005b; Ishino 
et al., 2005; van Djik et al., 2005), which may surrender their potential to be used as vaccines. 
Recently, successful induction of complete long-lasting immunity was also reported to be achieved by 
disruption of other sporozoite specific gene, the SAP-1 (sporozoite asparagine-rich protein-1) in P. 
yoelii (Aly et al., 2008). The sap1- parasites showed a phenotype comparable to the one of the WT 
regarding blood stage and mosquito infections, as well as migration and invasion of hepatocytes. 
Resembling what was described for the three aforementioned GAS, sap1- parasites showed complete 
early EEF development arrest (Figure 3. D) and, like the uis3- parasites, no breakthrough infections 
occurred, even when extremely high doses of sap1- sporozoites were injected into the mice. The sap1- 
parasites were shown to lack the expression of essential genes such as the UIS3, UIS4 and P36p 
genes, suggesting SAP-1 may be involved in a post-transcriptional mechanism of gene expression 
control, and that actually, more genes may be also abrogated in this parasite (Aly et al., 2008). This 
lack of several genes expression turns the sap1- parasite into an attractive GAS vaccine candidate 
due to its quasi-multi-loci attenuation.  
Altogether, the data obtained with rodent models GAS, especially of uis3- and sap1- parasites, 
have shown that safe and highly protective live attenuated malaria parasites can be created by genetic 
manipulation. Moreover, these studies may allow researchers to transfer the knowledge acquired to 
the development of a P. falciparum GAS, since all the aforementioned genes possess orthologues in 
other Plasmodium species, including P. falciparum (Mueller et al., 2005a; Mueller et al., 2005b; Ishino 
et al., 2005; Aly et al., 2008).  
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Recently, to assess the potential to create a GAS vaccine for human malaria, the P36p and the 
P36, a non-UIS gene encoding a putative secreted protein member of the 6-Cys domain protein 
family, genes were simultaneously disrupted in P. falciparum by double cross-over recombination 
gene replacement, to avoid genetic reversion and reconstitution of the WT locus (VanBuskirk et al. 
2009). The resulting p36p-/p36- parasites presented a phenotype comparable to the one of the WT 
parasite regarding the blood stage and mosquito stage infections, as well as hepatocyte migration and 
invasion processes. Moreover, P. falciparum p36p-/p36- parasites exhibited a profound EEF 
development arrest, and were not able to survive beyond the third day post infection (p.i.), both in vitro 
(using a human hepatic cell line) and in vivo (using chimeric mice carrying human hepatocyte 
transplant), and therefore, were unable to persist in a growth-arrested state (VanBuskirk et al. 2009). 
These results were in accordance with the ones obtained in the P. yoelii model in which P36p and the 
P36 orthologues were simultaneously disrupted. The P. yoelii p36p-/p36- parasite showed complete 
arrest of the EEF development after invasion without PV formation (Figure 3. D) and no breakthrough 
infections were reported. Besides, complete immunization against further challenges with WT 
sporozoites was achieved (Labaied et al.2007). Facing such a strong phenotype of EEF development 
arrest, as well as the promising results obtained using a rodent model, the P. falciparum p36p-/p36- 
parasite has been selected to advance into phase I clinical trials in human volunteers (Vaughan et al., 
2010).  
Altogether, these results, along with the technologies developed by Sanaria Inc., which can be 
adapted to GAS, indicate that it is feasible, in a somewhat near future, to generate a safe and efficient 
P. falciparum GAS vaccine that offers the advantages of genetic homogeneity, standardization, batch-
to-batch consistency and testable identity over the RAS, and even, the subunit candidates.  
LIFE AS AN INTRACELLULAR PATHOGEN – MODULATION OF HOST CELL APOPTOSIS 
Attenuated Plasmodium parasites, both RAS and GAS, are unable to fully develop inside the 
infected hepatocyte, arresting their development at early EEF stages. Several pieces of evidence have 
suggested that this may be due to their inability to prevent host cell apoptosis during development 
inside the hepatocyte.  
By living and developing within a host cell, intracellular pathogens are protected from immediate 
attacks by mechanisms of the host immune system. To achieve a successful intracellular life style, 
these pathogens have developed powerful methods to manipulate host cell functions in their own 
advantage, such as those involved in normal cell proliferation, cellular development and, specially, cell 
death by apoptosis, which is activated upon external or internal stimuli (van de Sand et al., 2005). 
Apoptosis is an active, highly specific and regulated, physiological process that plays an important role 
in tissue development and homeostasis, regulation and termination of immune responses and, 
importantly, in the removal of damaged or infected cells (reviewed in Carmen and Sinai, 2007).  
There are two main pathways leading to apoptosis in mammalian cells, the intrinsic and the 
extrinsic pathways, both converging on common effectors, the caspases (cysteine proteases that 
cleave after aspartate residues). Briefly, the extrinsic pathway is triggered by the activation of a death 
receptor on the cell plasma membrane surface (e.g. FasL) following the binding of an external ligand 
(e.g. Fas). This leads to the formation of the death-inducing signalling complex (DISC) that activates 
the initiator caspase, caspase 8 that further activates an effector one, the caspase 3. Once activated, 
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caspase 3 ultimately leads to cell death, by being responsible for multiple proteins activation. 
Meanwhile, the intrinsic pathway is initiated by internal signals like DNA damage or stress, and relies 
on the release of cytochrome c from the mitochondria. Once in the cytosol, cytochrome c interacts with 
the apoptosis activating factor 1 (Apaf-1) that oligomerizes to form an apoptosome, which in turn, 
recruits and promotes the activation of the initiator caspase 9, further activation of caspase 3 and, 
consequently, cell death (reviewed in Carmen and Sinai, 2007; James and Green, 2004). Both 
pathways are tightly regulated by multiple inhibitory or pro-survival mechanisms, such as the pro-
survival responses mediated by the phosphatidylinositol 3-kinase (PI3-K) pathway, known to interfere 
and inhibit apoptosis (reviewed in Carmen and Sinai, 2007). 
Although no inflammatory response is elicited when infected cells undergo apoptosis, phagocytes 
are attracted to the site, where they efficiently recognize and eliminate the apoptotic cell harbouring 
the intracellular pathogen. Throughout evolution, host cell apoptosis has therefore placed a strong 
selective pressure on intracellular pathogens, either virus, bacteria and parasites, to inhibit the host 
cell apoptotic machinery (Heussler et al., 2001). Among protozoans, Toxoplasma gondii, Theileria 
spp., Trypanosoma cruzi and Leishmania spp. are known to confer resistance to host cell apoptosis, 
and Plasmodium spp. is not an exception (reviewed in Carmen and Sinai, 2007). 
Once in the liver parenchyma, sporozoites traverse several hepatocytes before productively 
invading a final one with the formation of a PV (Figure 1. C). Upon traversal, wounded hepatocytes 
secrete hepatocyte growth factor (HGF), probably as a result of transient loss of their membrane 
integrity. HGF then binds to its tyrosine kinase receptor c-mesenchymal-epithelial transition factor (c-
MET) on the surface of neighbour hepatocytes (Carrolo et al., 2003), leading to the activation of the 
HGF/c-MET signalling. This then mediates the coordinated execution of multiple cellular processes 
that both render the hepatocytes more susceptible for infection (Carrolo et al., 2003) and lead to the 
activation of the pro-survival PI3-K pathway (Leirião et al., 2005a). Activation of the PI3-K pathway by 
HGF/c-MET signalling has been shown, both in vitro and in vivo, to prevent host cell apoptosis during 
the initial phases of hepatocyte infection (Leirião et al., 2005a). However, this has not been observed 
at later stages of EEF development, since HGF/c-MET signalling requirement during Plasmodium 
infection of hepatocytes occurs at the early stages of establishment and development of sporozoites 
within the host cell (Carrolo et al., 2003). Nevertheless, prevention of apoptosis during infection 
mediated by the PI3-K pathway may also be induced by other signalling pathways, or even be 
mediated by other pathways. This is supported by the report that sporozoite microneme protein 
essential for cell traversal (SPECT) disrupted P. berghei parasites, which lack the ability to migrate 
through hepatocytes, and therefore, to induce HGF secretion, are able to infect hepatocytes in vitro 
comparably to the WT parasites (Ishinho et al., 2004). At later phases of EEF development, the 
parasite grows and develops far beyond the normal size of the host cell (Figure 1. D), exerting an 
important stress factor on the infected hepatocyte. However, infected hepatocytes were reported to 
not exhibit signs of cell death and to be protected against apoptosis induced by several stimuli, both in 
vitro and in vivo (van de Sand et al., 2005). Actually, resistance to apoptosis seems to become more 
pronounced during the EEF development, and to be independent from the PI3-K pathway. It is more 
likely that at later stages of hepatocyte infection the parasite blocks potential pro-apoptotic factors, 
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most probably by secretion of parasite molecules, rather than stimulating host cell survival pathways 
(van de Sand et al., 2005). In the meantime, these mechanisms remain to be elucidated.  
Apparently, host cell protection from apoptosis requires that the parasite remains alive. There are 
indications that P. berghei RAS and P. berghei p36p- infected hepatocytes show evidence of 
apoptosis, like caspase-3 activation, shortly after invasion and early developmental phases. This 
suggests that these attenuated parasites, which are deficient in completing their development within 
the hepatocyte, fail to protect the host cell from entering in the apoptotic process (Leirião et al., 2005b; 
van Dijk et al., 2005). Interestingly, at the same time point, p36p- parasite-infected hepatocytes 
presented a significantly higher level of apoptosis than those infected with RAS, a difference that may 
be explained by the observed longer survival and development time of RAS within the host cell 
(Figure 3. B and D) (van Dijk et al., 2005). It appears that, the longer the attenuated parasite 
develops and survives within the host cell, the longer it is protected from apoptosis, maybe because 
the parasite, by arresting at an early stage of EEF development, lacks the capability of expressing 
factors that are essential for host cell apoptosis prevention, or by not developing further, ends up 
degenerating and subsequently, stops expressing the factors responsible for the protection. 
Surprisingly, it seems that within an infectious dose of WT parasites, some fail to prevent host cell 
apoptosis, maybe because they are deficient in some stage of their development, and end up 
degenerating (Leirião et al., 2005b; van Dijk et al., 2005). Nevertheless, this appears to be normal, 
occurring to a low percentage of WT parasites within an infectious dose.  
IMMUNE RESPONSES INDUCED BY RAS AND GAS 
As previously mentioned, immunization with live attenuated parasites elicits robust and long-lasting 
immune responses that completely protect against further infections. However, the nature of these 
immune responses is still not fully understood, although it appears that these may precisely be 
generated as a result from the fact that both RAS and GAS parasites fail to prevent host cell 
apoptosis. 
For practical and ethical reasons, the vast majority of the studies aiming to understand the immune 
responses triggered by RAS and GAS immunization protocols have been performed using 
Plasmodium parasite rodent model systems, mainly P. berghei and P. yoelii with laboratory mice from 
two major backgrounds, BALB/c and C57BL/6. Collectively, results indicate that the sterile immunity 
generated by RAS is of a multi-factorial nature, involving both humoral and cellular immune 
responses, respectively targeting the sporozoite and the infected hepatocyte (Jobe et al., 2009). 
Although it includes both CD4+ and CD8+ T cells responses, the protective immune response was 
reported to be primarily mediated by intrahepatic interferon-γ (IFN-γ) producing effector memory CD8+ 
T cells (TEM), accompanied by the presence of central memory CD8+ T cells (TCM) that endure 
homeostatic proliferation, forming a reservoir of memory T cells (Berezon et al., 2003). The 
importance of CD8+ T cell response is supported by the fact that immune protection by RAS is major 
histocompatibility class 1 (MHC-I)-dependent (White et al., 1996). 
It has been argued that the success of the protection conferred by RAS and GAS, is owed to the 
fact that they elicit immune responses that are broad-based against multiple antigen targets, both from 
the sporozoite and early EEF developmental stages (Hoffman and Doolan, 2000). Nevertheless, 
evidence that the antibody responses induced were predominantly directed against the antigenic 
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repetitive central domain of the CSP (Zavala et al., 1986), as well as that adoptive transfer of CSP-
specific CD8+ or CD4+ T cell clones was able to confer full protection against WT parasite sporozoite 
challenge (Romero et al., 1989; Rodrigues et al., 1991; Renia et al., 1993), led to the hypothesis that 
RAS-induced immune responses might be mediated by few immunodominant antigens, such as the 
CSP. In fact, this has prompted the development of subunit vaccines essentially based on CSP, such 
as the RTS,S and Sf66 vaccines (see above). However, the modest efficacies obtained by these 
vaccines, along with incongruous results obtained recently in two independent reports (Kumar et al., 
2006; Grüner et al., 2007), question the importance of immune responses against CSP in the 
induction and acquisition of sterile protection.  
Using BALB/c mice tolerant to P. yoelii CSP, therefore devoid of T cell dependent responses 
against CSP, Kumar et al., 2006 reported that CSP is a crucial antigen for the efficacy of RAS 
immunization. However, Grüner et al., 2007 demonstrated that sterile protection against P. berghei 
malaria can be induced independently of specific T cell immune responses to CSP. They have shown 
that BALB/c mice could be fully immunized by P. berghei RAS whose endogenous CSP had been 
replaced by the P. falciparum CSP, which does not elicit minimal T cells responses in those mice. 
Moreover, Mauduit et al., 2009 corroborated these later results, and actually proposed that this 
disparity could be due to the fact that immune responses against CSP and non-CSP antigens are 
induced differently in the two rodent malaria species. They have suggested that in P. berghei immune 
responses against non-CSP antigens, responsible for the sterile protection, are rapidly induced after 
RAS immunization, while in P. yoelii the responses arising rapidly are against CSP, being the ones 
targeting non-CSP antigens only achieved after several boosts with RAS. Nevertheless, it is still 
assumed that CSP is indeed the immunodominant antigen regarding the humoral responses, being 
the anti-CSP antibodies, generated after P. yoelii RAS, uis3- or uis4- parasite immunizations, able to 
neutralize infective sporozoites (Kumar et al, 2009).  
As mentioned, RAS-induced protective immunity is mainly mediated by IFN-γ producing CD8+ TEM 
cells. CD8+ T cells eliminate target cells mostly by engaging the perforin/granzyme B pathway to 
induce targeted cell apoptosis (cytotolytic activity). Here, through a pore formed by perforin, granzyme 
B is delivered to the targeted cell cytoplasm where it activates pro-apoptotic factors that ultimately lead 
to caspase-3 activation, or directly activates caspase-3 (James and Green, 2004). Surprisingly, 
protection against infection was successfully achieved in perforin as well as in granzyme B deficient 
mice after RAS immunization, suggesting that CD8+ T cells were primarily killing infected hepatocytes 
through other mechanism (reviewed in Vaughan et al., 2010). This scenario is actually logical if we 
take in consideration that infected hepatocyte apoptosis is inhibited by the developing parasite, and 
that this is one possible reason for the development of IFN-γ mediated CD8+ T cell immune response 
against infected cells, since IFN-γ affects the parasite indirectly, by inducing nitric oxide (NO) 
production in the infected cell. Nevertheless, cytolytic elimination of infected hepatocytes has also 
been reported, but appears to be less predominant than the IFN-γ mediated CD8+ T cell response (van 
de Sand et al., 2005). 
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HOW ARE RAS AND GAS IMMUNE RESPONSES TRIGGERED? – DCS COME INTO PLAY 
When infected cells undergo apoptosis, vesicles loaded with parasite antigens are formed 
(apoptotic bodies), that can thereafter be phagocytosed by antigenic presenting cells (APCs) such as 
macrophages and dendritic cells (DCs), and be further presented to the immune system, activating the 
subsequent specific immune responses. It has been hypothesized that this is precisely how protective 
immunity conferred by RAS or GAS is prompted (Leirião et al., 2005b; Jobe et al., 2009). 
DCs are key players in the coordination of immune responses against a variety of pathogens, and 
are separated into several cellular subsets, each with unique functional activities. For instance, the 
cCD8α+ DC subset is efficient in cross-presenting exogenous antigens (from extracellular sources, like 
apoptotic bodies) associated with MHC-I molecules to CD8+ T cells, activating them (Jobe et al., 
2009). Several pieces of evidence have suggested that DCs play an important role in the 
establishment of protective immunity induced by RAS, as mice devoid of DCs failed to develop 
protective immunity (Jung et al., 2002), and adoptive transfer of DCs loaded with P. yoelii CSP into 
naïve mice resulted in the generation of partial protective immunity (Bruña-Romero and Rodriguez, 
2001). Moreover, two elegant studies have revealed strong evidences that DCs are actually the 
vehicle that connects the apoptotic infected hepatocytes and the protective immunity, mainly mediated 
by CD8+ T cells responses (Leirião et al., 2005b; Jobe et al., 2009).  
Leirião et al., 2005b showed, by means of immunofluorescence observations of liver histological 
sections from BALB/c mice, that DCs are recruited to the liver early after infection with P. yoelii 
sporozoites or RAS. This fast recruitment of DCs to the site of infection may be due to the local 
inflammatory response that is induced by the wounded and dying cells during sporozoite migration, 
and that may actually be suitable for DCs further maturation, since proper stimulatory signals may be 
present. Furthermore, this study also found macrophages and DCs carrying vesicles with parasite 
antigens at 6h p.i., when RAS-infected hepatocyte apoptosis was firstly reported. These vesicles were 
confirmed to be from apoptotic infected cell origin and not from single sporozoites since they 
contained Hsp70, a parasite protein not expressed in the sporozoite but in the EEF stages (Kumar et 
al., 1993), mouse albumin, a protein present within the hepatocyte cytoplasm, and activated caspase-
3. Altogether, these results strongly suggest that indeed, apoptotic bodies originated from apoptotic 
RAS infected hepatocytes origin are phagocytosed by DCs in the liver. However, the study did not 
address whether these DCs were able to activate the effective CD8+ T cell responses, a subject that 
was further analyzed by Jobe et al., 2009.  
In Jobe et al., 2009, C57BL/6 mice were immunized with a P. berghei RAS immunization protocol, 
comprising a prime immunization and two subsequent boosts, during which the levels of DCs and 
CD8+ T cells were followed, both in the liver and in the spleen. They showed that the cCD8α+ DC 
population in the liver, nearly absent in naïve mice, accumulated during the course of the repeated 
immunizations with RAS, reaching the maximum level after the second boost, and that in fact, this  
coincided with the expansion of CD8+ TEM cells in the liver. The levels of both cells also increased in 
the spleen, but this was not as marked as in the liver. Moreover, they showed that this cCD8α+ DC 
subset was indeed the primary inducers of the CD8+ TEM cell response through an experiment in which 
the co-culture of cCD8α+ DCs from immunized mice, with CD8+ T cells from naïve mice, lead to the 
acquisition of the IFN-γ secreting TEM phenotype by the CD8+ T cells. The cCD8α+ DC subset was also 
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shown to exhibit high levels of MHC-I and to be an efficient producer of IL-12, the key cytokine 
promoting the activation of CD8+ T cells. In fact, activation of CD8+ T cells by liver cCD8α+ DCs from 
immunized mice was dependent on both MHC-I and IL-12. To finally proof that these liver cCD8α+ 
DCs were indeed responsible for the activation of the CD8+ TEM cell responses, they were adoptively 
transferred to naïve mice and actually, were able to confer protective immunity against further 
challenges with small doses of P. berghei sporozoites. Facing these results, the authors propose that 
liver cCD8α+ DCs cross-present P. berghei pre-erythrocytic antigens derived from apoptotic P. berghei 
RAS infected hepatocytes to liver CD8+ T cells, activating them into IFN-γ secreting CD8+ TEM cells. 
Nevertheless, they were not able to completely infer whether this priming occurs in the liver, in the 
draining lymph node or in the spleen.  
Recently, it was shown that P. yoelii CSP persists for more than 8 weeks after immunization with 
RAS, not because of parasite persistence as an arrested pre-erythrocytic stage, but because the 
antigen is transferred to other cell types, such macrophages and DCs present in the liver, spleen and 
lymph nodes (Cockburn et al., 2010). This antigen persistence appears to be able to enhance immune 
responses to the parasite by maximizing the size of the CD8+ TEM cell population, inducing proliferation 
of CD8+ TCM cell population, and by recruiting and promoting differentiation of naïve CD8+ T cells from 
the thymus, into CD8+ TEM cells (Cockburn et al., 2010).  
Antigen persistence may therefore be one of the factors accounting for the observed long-lasting 
durability of the protective immunity induced by attenuated sporozoites, and an additional evidence for 
the importance of DCs in the establishment and persistence of such immune response.  
AIM  
The aim of the present project was to test the hypothesis that apoptosis of infected hepatocytes 
with attenuated parasites, either RAS or GAS, is essential for the establishment of complete protective 
immunity, known to be induced by immunization with these parasites, against further challenges with 
infectious sporozoites.  
To address this question, C57BL/6 background mice deficient in caspase-3 (Casp3KO mice), 
which, as already mentioned, is a key player in numerous apoptotic pathways, were immunized with 
either P. berghei RAS or P. berghei p36p- sporozoites. Challenge infections were further performed 
with either green fluorescent protein (GFP) – expressing P. berghei ANKA (PbGFP, Franke-Fayard et 
al., 2004) or luciferase – expressing P. berghei ANKA (PbLuci, Ploemen et al., 2009) sporozoites. In 
these parasites, the GFP and Luciferase genes are under the control of strong housekeeping gene 
promoters, being constitutively expressed in a growth responsive manner throughout the respective 
parasites life cycle. This feature allows the establishment of a correlation between the parasite load in 
the liver with the expression of GFP or luciferase in the liver of infected mice when assesses through 
appropriate established methodologies, quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) (Bruña-Romero et al., 2001), and real-time in vivo imaging (Ploemen et al., 2009), 
respectively. The level of infection in the liver was used as a means to infer acquisition of immunity, 
although the efficiency of the immune response was only ultimately assessed by following the 
appearance and progression of the blood stage infection, by counting the percentage of parasites in 
the mice peripheral blood (parasitemia) (Mueller et al., 2005a).  
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In order to exclude the involvement of a deficient immune system responses in the outcome of 
Casp3KO mice immunization, bone marrow chimeric mice, either expressing caspase-3 exclusively in 
haematopoietic cells (Casp3KO mice reconstituted with C57BL/6 mice bone marrow) or in non-
hematopoietic cells (C57BL/6 mice reconstituted with Casp3KO mice bone marrow), were generated, 
and immunized with PbGFP-RAS. 
Moreover, a breakthrough methodology to detect apoptosis in vivo, that combines fluorescent 
probes with a pan-caspase inhibitor, was also used to compare the level of apoptosis in the liver of 
mice infected with RAS and NIrr sporozoites.  
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MATERIALS AND METHODS 
MICE 
Six to twelve-week old male and female C57Bl/6 mice (from Instituto Gulbenkian de Ciência, 
Charles River Laboratories, or Harlan Ibèrica) and C57BL/6 background caspase-3 deficient mice 
(Casp3KO mice) (Kuida et al., 1996) (bred in the Animal House of the Instituto de Medicina Molecular 
– IMM) were used. In each experiment, groups were formed by mice from the same age range, gender 
and, in the case of the C57Bl/6 mice, from the same supplier, to exclude variation within groups due to 
either age, gender or supplier related heterogeneity. Casp3KO mice were genotyped by tail genomic 
DNA Polymerase Chain Reaction (PCR) using primers (5’-TGACTGGGCACAACAGAC-3’; 5’-
TTTCTCGGCAGGAGCAAG-3’) targeting a 271 bp fragment of the neomycin resistance cassette used 
to generate them (Kuida et al., 1996). The following amplification programme was used: 95ºC/5 min of 
initial denaturation, followed by 25 cycles of 95ºC/30 sec, 61ºC/30 sec and 72ºC/17 sec, and a final 
round of 72ºC/10 min to allow complete elongation of the PCR product. Protocols involving live 
animals were approved by the Animal Care Committee of the IMM. 
PARASITES 
Green Fluorescent Protein (GFP) – expressing Plasmodium berghei ANKA (PbGFP, parasite line 
260 cL2) (Franke-Fayard et al., 2004), genetically attenuated P36p deficient GFP – expressing P. 
berghei ANKA (Pbp36p-, parasite line 274 cL1.1) (van Dijk et al., 2005), and Luciferase – expressing 
P. berghei ANKA (PbLuci, parasite line 676 m1cL1) (Ploemen et al., 2009) sporozoites were used. 
Sporozoites were obtained by removal and disruption of salivary glands from freshly dissected 21-35 
days – infected female Anopheles stephensi mosquitoes, bred at the Insectary of the IMM. After 
dissection, salivary glands were collected in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco/Invitrogen), further disrupted, and passed through a 70 μm pore diameter cell strainer. 
Sporozoite’s concentration was then determined by counting their number in a Neubauer chamber 
(Average of sporozoites per quadrant x 104 x dilution factor), that was previously maintained in a moist 
chamber for 10 minutes. Radiation attenuated PbGFP sporozoites (PbGFP-RAS) were obtained by 
exposing freshly obtained PbGFP sporozoites to a 16 krad dose of γ-radiation (Orjih et al., 1982) on a 
Compagnie Oris Industrie IBL 437C irradiator (in all experiments involving mice) or MDS Gamma Cell 
3000 Elan irradiator.  
PbGFP-RAS FITNESS – IN VITRO GLIDING, MIGRATION, INVASION AND DEVELOPMENT 
ASSESSMENT 
For gliding motility assessment, glass coverslips were coated with 10 μl/ml of anti-circumsporozoite 
protein (CSP) 3D11 antibody (Ab) and incubated for 1h at 37ºC. Coverslips were then washed with 
PBS and 30.000 sporozoites were added per coverslip in complete RPMI 1640 medium 
(Gibco/Invitrogen). Subsequently, they were centrifuged for 5 min at 3000 rpm, and incubated for 30 
min at 37ºC. Coverslips were then washed with PBS, fixed for 15 min in 4% paraformaldehyde (PFA) 
at room temperature (RT), and further incubated for 30 min with 10 % fetal calf serum (FCS, 
Gibco/Invitrogen). Afterwards, they were incubated for 1h with 0,03 mg/ml anti-CS 3D11 Ab, followed 
by 1h incubation with a goat anti mouse (GAM) alexa fluor 488 Ab (Invitrogen), both at RT. Finally, the 
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coverslips were washed with PBS, and mounted on slides with Fluoromount (Southern Biotech). 
Gliding motility was assessed by counting the average number of circle trails left by single sporozoites 
per coverslip (15 fields, 200x amplification) on a Leica DM5000B Widefield Fluorescence Microscope. 
For migration, invasion and development appraisement, flow cytometry (FC) was used, as 
described in Prudêncio et al., 2008. Huh7 cells, a human hepatoma cell line, were cultured and 
maintained in complete RPMI medium (Gibco/Invitrogen) as described. For each assay, an average of 
70.000 cells/well was seeded on 24-well plates the day before infection. Cells were infected with an 
average of 30.000 sporozoites/well,  further centrifuged for 5 min at 3000 rpm, and incubated at 37ºC 
and 5% of CO2 for 2h (migration and invasion), or 48h (development). In the case of migration 
evaluation, 2 mg/ml Dextran tetramethylrhodamine 10 000 MW, lysine fixable (fluoro-ruby) (Molecular 
Probes/Invitrogen), in RPMI complete medium, were added to the Huh7 cells immediately prior to 
infection. At the appropriate time point post infection (p.i.), cells were washed in PBS, incubated with 
trypsin (Gibco/Invitrogen) for 5 min at 37ºC, and collected in 10% FCS. Cells were then centrifuged for 
5 min at 1200 rpm, further re-suspended in 2% FCS, and analyzed on a Becton Dickinson (BD) 
FACScalibur Flow Cytometer with the appropriate settings for GFP and Dextran tetramethylrhodamine 
detection. Data acquisition and analysis were performed as described in Prudêncio et al, 2008, using 
CELLQuest Pro (Becton Dickinson) and FlowJo (version 6.4.7, Tree Star, Inc 1997-2006) software 
packages, respectively. 
P. berghei INFECTION PROGRESSION IN CASP3KO MICE 
Groups of C57BL/6 and Casp3KO mice were infected intravenously (i.v.) in the retro-orbital venous 
plexus with 10.000 PbGFP or PbLuci sporozoites, depending on whether Quantitative Real-Time 
Reverse Transcription PCR (qRT-PCR), or in vivo Real Time Imaging, respectively, were employed to 
measure liver stage infection. In experiments where infection was allowed to proceed to the blood 
stage, Giemsa-stained thin peripheral blood smears were prepared from individual mice from day 3 up 
to 3-4 weeks after infection. The percentage of parasitized erythrocytes (parasitemia) was determined 
microscopically (Number of parasitized erythrocytes / Number of total erythrocytes x 100). 
IMMUNIZATION WITH PbGFP-RAS OR PbP36P-GAS AND PARASITE CHALLENGE EXPERIMENTS 
Groups of C57BL/6 and Casp3KO mice were immunized with either PbGFP-RAS or Pbp36p- 
sporozoites, as previously described (Orjih et al., 1982, Douradinha et al., 2007). Both groups were 
injected i.v. with three immunization doses, 8 days apart, of 10.000 PbGFP-RAS or 2.000 Pbp36p-. 
Eight to 12 days after the last immunization, mice were challenged i.v. with 10.000 PbGFP or PbLuci 
sporozoites. In every immunization and challenge experiments, a group of non-immunized C57BL/6 
mice was challenged, at the same time as the immunized groups, to confirm the infectivity of the 
challenge dose. In experiments where infection was allowed to proceed to the blood stage, blood 
parasitemia was followed as already described. 
QUANTIFICATION OF PbGFP LIVER INFECTION BY qRT-PCR  
Livers were collected from mice 40-44h after infection/challenge with PbGFP sporozoites, and 
mechanically homogenized in denaturating solution (4 M guanidine thiocyanate; 25 mM sodium citrate 
pH 7; 0,5% N-Lauroyllsarcosine; and 0,7% of freshly added β-mercaptoethanol, in 
Diethylpyrocarbonate (DEPC)-treated water). Total RNA was further extracted using RNeasy Total 
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RNA Mini Kit (Qiagen), and converted into cDNA using Transcriptor First Strand cDNA Synthesis Kit 
(Roche), according to the manufacturer’s protocols and the amplification programme: 25ºC/10 min, 
55ºC/30 min and 85ºC/5 min. Equal amounts of cDNA per sample were then amplified by qRT-PCR 
using Finnzymes F-410XL DyNAmo™ HS SYBR® Green qPCR Kit with primers targeting P. berghei 
18S rRNA (5’-AAGCATTAAATAAAGCGAATACATCCTTAC-3’; 5’-GGAGATTGGTTTTGACGTTTATG 
TG-3’), or mouse hypoxanthine guanine phosphoribosyl transferase (HPRT) housekeeping gene (5’-
GTAATGATCGTCAACGGGGGAC-3'; 5’-CCAGCAAGCTTGCAACCT TAACCA-3’) transcripts. The 
amplification reaction was performed in an Applied Biosystems 7500 Fast Real-Time PCR System, 
using the instrument’s standard ramp speed and the amplification programme: 50ºC/2 min and 
95ºC/10 min, followed by 50 cycles of 95ºC/15 sec and 60ºC/1 min, and one cycle of 95ºC/15 sec, 
60ºC/1 min, 95ºC/30 sec and 60ºC/15 sec. Parasite load was obtained by calculating the relative 
amounts of P. berghei 18S cDNA copies (although primers targeting GFP cDNA could also be used 
since the expression of both genes correlates positively, Prudêncio et al., 2008) against HPRT cDNA 
copies, per mouse liver.  
The level of CD8+ T cells in the liver was assayed using the same procedure with primers targeting 
CD8 cDNA copies (5’-GCTGGTAGTCTGCATCCTGCTTC-3’; 5’-TTGCTAGCAGGCTATCAGTGTTGT 
G-3’). CD8+ T cells load was obtained by calculating the amounts of CD8 cDNA relative to HPRT 
cDNA, per mouse liver.  
QUANTIFICATION OF PbLUCI LIVER INFECTION BY REAL-TIME IN VIVO IMAGING  
At 40-44h after infection/challenge with PbLuci sporozoites, mice were examined by Real Time 
Imaging as described in Ploemen et al., 2009. Briefly, mice were anesthetized with isoflurane (IsoFlo, 
Veterinária Esteves) and immediately injected subcutaneously (in the neck) with D-Luciferin dissolved 
in PBS (0,15 mg/g, Caliper Life Sciences). Precisely 5 min after, mice were intra-peritoneally (i.p.) 
injected with 200 μl of an anaesthesia mixture comprising Ketamine (1,2% of Imalgene 1000, Merial) 
and Xylazine (0,8% of 2% Rompun, Bayer), diluted in PBS, and placed inside the imaging camera of 
the in vivo Imaging System (IVIS® Lumina Imaging System). Bioluminescence imaging was acquired 
exactly 10 min after D-Luciferin injection, with a 12.5 cm field of view (FOV), binning factor of 4, and an 
exposure time of 180 seconds. Quantitative analysis of bioluminescence was performed by measuring 
the luminescence signal intensity using the region of interest (ROI) settings of the Living Image® 
Software (version 3.0). The ROIs were set to measure the abdominal area (that was previously 
shaved using chemical depilatory, Veet®) at the location of the liver. ROI measurements were 
expressed in total flux of photons, and were used to infer liver stage infection. 
CASP3KO BONE MARROW CHIMERIC MICE 
Chimeric mice were generated as described in Cunha-Rodrigues et al., 2007, with slight 
adaptations. In two separate sessions of 450 rad (2h apart, minimum), recipient C57BL/6 and 
Casp3KO mice were lethally γ-irradiated with an overall dose of 900 rad. Bone marrow from donor 
C57BL/6 and Casp3KO mice was removed from the major leg bones, femur and tibia, by flushing in 
4% FCS at 4ºC, with a 27G syringe. The bone marrow was gently flushed until a homogenized 
suspension of cells was obtained. This was then passed through a 100 μm diameter pore cell strainer, 
and cell concentration was calculated by counting their number in a Neubauer chamber (Average of 
cells per quadrant x 104 x dilution factor). Cells were then centrifuged for 5 min at 1200 rpm, and re-
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suspended in PBS in a volume suitable to i.v. inject 6,5 x 106 cells per recipient mouse. Recipient 
C57BL/6 mice were subsequently reconstituted with bone marrow cells from donor Casp3KO mice 
(ChimC57BL/6), while recipient Casp3KO mice were reconstituted with bone marrow cells from donor 
C57BL/6 (ChimCasp3KO). An additional group of C57BL/6 mice that was also lethally γ-irradiated but 
was not reconstituted, and was left depleted from bone marrow cells, to serve as irradiation control 
group. These three groups were treated with a wide spectrum antibiotic, Trimetoprim/Sulfametoxazol 
(40 mg + 200 mg, Bactrim® paediatric suspension, Roche) diluted in the drinking water (1:50), from 
day 2 before irradiation until 4 weeks after irradiation. Chimeric mice were allowed to recover for 8 
weeks, to allow the irradiation control group to succumb naturally, before any procedure was 
performed on them. Afterwards, chimeric mice were immunized with PbGFP-RAS, and subsequently 
infected with PbLuci, as described above. Depletion of circulating cells and reconstitution with donor 
cells was confirmed in all chimeric mice by PCR of blood genomic DNA. Blood was collected from the 
tail and DNA extracted using DNeasy Blood and Tissue Kit (Qiagen). PCR was performed using two 
sets of primers that amplify sequences either from the knock out (same pair of primers and 
amplification programme used for genotyping, as described in Mice) or the wild type allele (5’-
TGTCATCTCGCTCTGGTACG-3’; 5’-AAATGACCCCTTCATCACCA-3’; 1250 bp), the later with the 
amplification programme: 95ºC/5 min of initial denaturation, followed by 35 cycles of 95ºC/1 min, 
58ºC/1 min, and 72ºC/1 min 30 sec, and a final round of 72ºC/10 min, to allow  complete elongation of 
the PCR product. 
IN VIVO DETECTION OF APOPTOSIS IN THE LIVER 
Groups of C57BL/6 and Casp3KO mice were i.v. infected with either PbGFP or PbGFP-RAS 
(100.000 – 280.000 sporozoites/mouse). As negative controls, two groups of C57BL/6 mice were not 
infected, while as a positive control, another group of C57BL/6 mice was i.v. injected with 5 μg/20 g of 
purified mouse anti-Fas/CD95/APO-1 monoclonal antibody (α-Fas, Pharmingen) (Imao et al., 2005). 
At 5h 30 min p.i., the infected groups, the α-Fas injected group, and one of the non-infected groups 
were injected i.v. with the red fluorescent probe SR-FLIVOTM (SR-VD-FMK, sulforhodamine-B 
conjugated valylalanylaspartic acid fluoromethyl ketone; ImmunoChemistry Technologies, LLC), 
prepared according to the manufacturer’s protocol. In each experimental set, mice were injected with 
similar amounts of SR-FLIVOTM (13,1 – 16,4 μg/mouse). SR-FLIVOTM was allowed to circulate for 
about 30 min, after which mice were i.p. injected with a Ketamine and Xylazine anaesthesia mixture, 
and placed inside the imaging camera of the in vivo Imaging System (IVIS® Lumina Imaging System). 
Fluorescence imaging was acquired using DsRed as excitation and ND3 as emission filters, with a 
FOV of 12,5, a binning factor of 8, and an exposure time of 1 sec. Subsequently, livers were removed, 
and analysed again by fluorescence imaging, using the same image settings as before. 
TRANSGENIC PARASITE – PRO-CASPASE-2 EXPRESSING AND EXPORTING P. berghei 
The pro-caspase-2 insert (1371 bp) was amplified by PCR from C57BL/6 mice liver cDNA, using 
designed primers with inserted restrictions sites (Table 1.), and the amplification programme: 95ºC/5 
min of initial denaturation, followed by 35 cycles of 95ºC/30 sec, 56ºC/30 sec and 72ºC/1 min 30 sec, 
and a final round of 72ºC/10 min. Meanwhile, CSP promoter (pCS, 1047 bp) and pexel motif (242 bp) 
inserts were amplified from P. berghei ANKA genomic DNA, using primers designed with a site 
mutagenesis and inserted restrictions sites (Table 1.), and the respectively amplification programmes: 
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95ºC/5 min of initial denaturation, followed by 35 cycles of 95ºC/30 sec, 43ºC/30 sec and 62ºC/1 min, 
and a final round of 62ºC/10 min (pCS); 95ºC/5 min of initial denaturation, followed by 35 cycles of 
95ºC/30 sec, 41ºC/30 sec and 62ºC/20 sec, and a final round of 62ºC/10 min (pexel motif). 
In total, six plasmids (Plasmid A to Plasmid F, Figure 9.) were planned to be constructed in a 
modular fashion. All constructs were assembled on two backbone plasmids, the pcDNA 3.1 (+) 
plasmid (Invitrogen), to allow in vitro tests, and the pVIII plasmid (courtesy of Gunnar Mair’s laboratory, 
Figure 4.), that will be ultimately transfected into parasites. Briefly, to construct the six plasmids, both 
inserts and backbone plasmids were incubated with the appropriate restriction enzymes and 
compatible buffers (all from Fermentas, Table 1.) for 1h at 37ºC, and further purified using the High 
Pure PCR Product Purification Kit (Roche). Next, ligation was performed, by incubating both insert and 
plasmid with ligase and respective buffer (Fermentas), at proportions of 5:1 and 3:1, overnight at 15ºC. 
Afterwards, competent E. Coli DH5α cells (Invitrogen) were added to the ligation mix, incubated for 20 
min at 4ºC, and later subjected to a heat chock 45 sec at 42ºC, followed by a short incubation of 2 min 
at 4ºC. Subsequently, cells were grown in liquid lysogeny broth (LB) medium without ampicillin for 45 
min at 37ºC, and further plated on LB agar medium supplemented with ampicillin (1000x concentrated, 
100 μl/ml) overnight. Single grown colonies were then 
collected and grown in liquid LB medium supplemented 
with ampicillin (1000x concentrated, 100μl/ml) 
overnight. Afterwards, cultures were centrifuged for 5 
min at maximum speed, and the pellet resuspended in 
260 μl of STET (8g of sucrose, 5g of TritonX-100, 10 
ml of 0,5 M EDTA, and 5 ml of Tris-HCL 1 M pH 8), to 
which 40 μl of lysozyme was freshly added. 
Immediately after, it was boiled for 1 min, and 
centrifuged at maximum speed for 15 min at 4ºC. The 
pellet was then discarded, and 400 μl of isopropanol 
were added to the supernatant. The resulting mixture 
was thoroughly vortexed and further incubated for 10 
min at 4ºC, for plasmid precipitation. The pellet was 
then dried and further resuspended in 100 μl of water 
Gene 
(accession number) Primer Sequence 
Introduced 
Restriction Sites 
Pro-Caspase-2 
(NM_007610) 
Forward CTCGGATCC BamHI GAAATGGCGGCGCCGAGC 
Reverse TTTTCTAGACGCGGCCGC NotI and XbaI ACGTGGGTGGGTAGCCTGG 
CS Promoter 
(PBANKA_040320) 
Forward AAAGAATTC EcoRI AAATATGCAAGATGG 
Reverse CATATTTAAAT SwaI ATATGCG 
CS PEXEL motifs 
(PBANKA_040320) 
Forward GCATATATTTAAAT SwaI ATGAAG 
Reverse TTTGGATCC BamHI TTCGGGAGCATCGGC 
Table 1. Primers used to amplify the target region of each gene. The restriction sites introduced to allow plasmid construction 
were highlighted in the sequences, and the restriction enzymes identified. A site mutagenesis was also inserted in both CS 
promoter and CS PEXEL motifs pair of primers (highlighted in red). 
Figure 4. pVIII plasmid. Courtesy of Gunnar Mair’s 
laboratory. Has a DHFR-TS and ampicillin 
resistance markers. Restriction sites are 
represented. 
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with 20 μl/ml of RNase. The correct ligation of the insert into the isolated plasmid was further 
confirmed both by enzymatic restriction and sequencing (Stabvida).  
Pro-caspase-2 activity was tested in vitro, using Hepa 1-6 cells, a C57L/J mouse hepatoma cell 
line, that were maintained in DMEM medium supplemented with 10% FCS, 1% Penicillin/Streptomycin 
and 1% L-glutamine (all from Gibco/Invitrogen), at 37ºC and 5% of CO2. For each experiment, non 
transfected cells, cells transfected with the constructed plasmid (Plasmids A, D or E), and cells 
transfected with pcDNA 3.1 (+) plasmid alone were used. An average of 80.000 cells per well of a 24-
well plate were transfected with 0,4 μg of plasmid and 1,8 μl of Fugene 6® Transfection Reagent 
(Roche), according to the manufacturer protocol. Cells were then plated on glass coverslips in a 24-
well plate and incubated at 37ºC and 5% of CO2 until analysis was performed at 24, 25, 26, 30 and 
50h later. Upon analysis, cells were incubated with DMEM medium with 1:20 of AlamarBlue® 
(Invitrogen) for 1h 30 min at 37ºC, after which were analysed on a Infinite 200 plate reader using the 
following parameters: excitation wavelength of 530 nm, emission wavelength of 590 nm, number of 
flashes of 10, gain of 100 and mode top reading.  
After testing in vitro if the final construct is functional (Plasmids D and E), Plasmid C or F 
(depending on whether the construct functions when fused to GFP), will be linearized by cutting with 
SwaI and transfected into P. berghei ANKA blood schizont stages through electroporation, as 
described in Janse et al., 2006. Blood schizont stages will then be injected into BALB/c mice and 
further selected by treatment with pyrimethamine. Further, transgenic parasites will be genotyped 
using primers targeting the inserts of the construct (Table 1.). Afterwards, mosquitoes will be infected 
with the transgenic parasite, where its development will be characterized; sporozoites will be 
characterized for in vitro gliding motility, migration, invasion and development, as well as their ability to 
infect and develop in C57BL/6 mice. If the construct is efficiently expressed and induces apoptosis of 
the infected hepatocytes, C57BL/6 will be infected with the transgenic parasites (the number of 
infections will be determined) and followed-up for the establishment of protective immunity against 
further challenge with infectious sporozoites (PbGFP or PbLuci).  
STATISTICAL ANALYSIS 
Statistical analysis was performed using unpaired Student t Test, on Microsoft Excel. 
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RESULTS AND DISCUSSION 
INFECTION WITH P. berghei ANKA – A VARIABLE OUTCOME FOR CASP3KO MICE 
Thamnomys surdaster, an African tree rat, is the natural host of Plasmodium berghei. Because it is 
not amenable to routine use in the laboratory, several inbred strains of mice have been evaluated to 
best replace it for laboratory studies, such as the BALB/c, DBA and C57BL/6 strains. Scheller et al., 
1994, demonstrated that the system C57BL/6-P. berghei ANKA is an optimal model to study the 
biology of pre-erythrocytic stages of the parasite (that take 40-44h to fully develop in this model), and 
the cellular protective mechanisms elicited after immunization with P. berghei radiation attenuated 
sporozoites (PbRAS). Moreover, C57BL/6 mice are susceptible to the development of cerebral malaria 
(CM) by P. berghei ANKA erythrocytic stages, a very reproducible phenotype characterized by 
neurologic signs, such as paralysis, ataxia, convulsions and coma, accompanied by a relatively low 
percentage of infected erythrocytes (parasitemia), below 10%, at the time of death. Generally, CM 
occurs within 7-9 days p.i., with a cumulative mortality of nearly 90%. Nonetheless, about 10% of the 
mice do not develop CM and eventually succumb during the following 3 to 4 weeks from severe 
anaemia and hyperparasitemia, without neurological signs (Jennings et al., 1997; Lou et al., 2001).  
Therefore, in the present work, C57BL/6 mice and C57BL/6 background mice deficient in caspase-
3 (Casp3KO mice) were used, along with several P. berghei ANKA parasite lines: expressing the GFP 
or luciferase genes (PbGFP or PbLuci, respectively), attenuated by irradiation (PbGFP-RAS), and 
attenuated by genetic modification (Pbp36p-). 
Prior to addressing if Casp3KO mice could be successfully immunized by attenuated parasites, the 
outcome of P. berghei ANKA infection of Casp3KO and C57BL/6 mice, regarding both liver and blood 
stages of infection, was compared. Pre-erythrocytic stages of Plasmodium are known to prevent host 
cell apoptosis both during their early and late development (Leirião et al., 2005a; van de Sand et al., 
2005). Nevertheless, some parasites in an infective population are unable to prevent the host cell from 
undergoing apoptosis (Leirião et al., 2005b; van Dijk et al., 2005). Hence, it would be expected that in 
Casp3KO mice, which lack a crucial player of the major apoptotic pathways (Carmen and Sinai, 2007), 
the parasite load in the liver would be higher, or at least, similar to that observed in C57BL/6 mice, as 
even the parasites that may fail to prevent host cell apoptosis would be able to fully develop.  
In two independent assays, both groups of mice were infected i.v. with 10.000 sporozoites, PbGFP 
or PbLuci, and liver stage infection was assessed at 40-44h p.i., by qRT-PCR (Figure 5. A) or real 
time in vivo imaging (Figure 5. B), respectively. Since the analysis of liver infections with PbLuci by 
whole body imaging shows a good correlation with qRT-PCR analysis of extracted livers from infected 
mice (Ploemen et al., 2009), it is possible to compare the two assays. Unfortunately, it was not 
possible to draw any definite conclusions from both assays, as there were no statistically significant 
differences between the two experimental groups (Figure 5. A and B). Interestingly, the Casp3KO 
mice group showed an unexpectedly lower level of parasite load than the average level of the 
C57BL/6 group, and the reasons why remain unclear. One reason may be the existence of other 
caspase-3-independent apoptotic pathways, as well as of other highly related and even structurally 
similar to caspase-3 effector caspases, like caspase-7, that may compensate for caspase-3 loss and 
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lead to apoptosis of caspase-3 deficient cells (Lakhani et al., 2006). This could be further evaluated by 
immunofluorescence detection of other effector caspases like, for example, activated caspase-7 in 
infected Casp3KO primary hepatocytes. 
Unlike qRT-PCR, which requires sacrificing the mice in order to mesaure liver parasite load, PbLuci 
real-time in vivo imaging enables assessing liver stage infection in live mice that can be further 
followed to monitor the development of blood stage infection (Ploemen et al., 2009). Therefore, blood 
stage infection was followed in an adicional group of mice infected with PbGFP, and the original 
groups infected with PbLuci (Figure 5. C). Blood stage infection was followed by counting individual 
mice parasitemia in thin peripheral blood smears stained with Giemsa, that strongly stains the DNA of 
the parasite and faintly the shape of the erythrocyte, which is an enucleated cell (Fleischer, 2004). 
From the groups infected with PbGFP, only two (n=5) C57BL/6 mice developed clear symptoms of 
CM and perished within the CM time window, with an average parasitemia of 3,36% (Figure 5. C and 
D). The other 3 mice did not develop neurological signs, and perished by day 16 p.i., most likely due to 
the development of anaemia. Interestingly, none of the infected Casp3KO mice (n=5) developed CM 
symptoms, although 2 mice did succumb within the expected time window with an average 
parasitemia of 4,37% (Figure 5. C and D). The other 3 mice did not develop any neurological signs 
and died only at day 20 p.i. with severe anaemia and hyperparasitemia, in the range of the 40% 
(Figure 5. C and D).  
Figure 5. Casp3KO mice infection with P. berghei ANKA. A) PbGFP liver stage infection at 40h p.i., assessed by qRT-PCR. 
The two groups are not significantly different (p>0,05, Student t test). B) PbLuci liver stage infection at 44h p.i., assessed by real 
time in vivo imaging. The two groups are not significantly different (p>0,05, Student t test). Bi) Rainbow images of luminescence 
in livers of live mice after luciferin injection, showing the relative levels of luminescence ranging from low (blue), to medium 
(green) and to high (yellow/red), and from where the graphic in B) was derived. C) Survival curve representing the % of live 
mice from the same experiments as A) and B) throughout the blood stage infection follow up. D) Table representing the day, 
average % of parasitemia and the cause of death of the mice represented both in B) and C). 
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In the groups infected with PbLuci, all C57BL/6 mice developed CM within the expected time 
window with an average parasitemia of 4,07%, while the group of Casp3KO mice behaved similarly as 
in the above discussed assay (Figure 5. C). Interestingly, there was no observable correspondence 
between the levels of parasite load in the liver and the progression of blood stage infection, although it 
would to be expected that mice with higher parasite load in the liver would develop severe disease or 
higher parasitemia earlier than the others with a lower load.  
Together, these results suggest that Casp3KO mice are resistant to CM development by P. berghei 
ANKA, although they eventually perish from one of two outcomes, either within the CM time window 
and parasitemia range, without neurological sings, or with severe anaemia and hyperparasitemia. The 
detection of activated caspase-3 in the brains of P. berghei ANKA infected mice with clinical signs of 
CM, mainly in neurons, oligodendrocytes, and endothelial cells, has suggested that apoptosis of 
endothelial cells may represent a critical step for the development of CM, and that the neurological 
signs and symptoms may be, at least in part, attributable to the apoptotic degeneration of neurons and 
glia in advanced stages of CM (Lackner et al., 2006). Since the Casp3KO mice lack caspase-3, and 
the active form of this enzyme appears to have an important role in the establishment and 
development of CM, it is plausible that this may be one of the possible reasons for the observed 
phenotype. 
P. berghei ANKA RAS – THE EXPECTED PHENOTYPE 
PbRAS are very efficient in generating immunity in C57BL/6 mice (van Dijk et al., 2005). 
Nevertheless, the application of radiation to attenuate the parasite poses reservations regarding its 
safety and reproducibility, as improper irradiation of parasites may allow them to remain infectious and 
cause disease (Ballou, 2007). Properly attenuated PbRAS retain their ability to invade hepatocytes 
comparable to the non-irradiated (NIrr) sporozoites, although they fail to fully develop within the host 
cell (Suhrbier et al., 1990). To ensure that the parasites herein used were being properly attenuated, 
and to test the reproducibility of two different irradiators, a simple in vitro assay comparing PbGFP-NIrr 
and PbGFP-RAS, either obtained by irradiation of PbGFP sporozoites on a Compagnie Oris Industrie 
IBL 437C irradiator (PbGFP-IrrHosp) or on a MDS Gamma Cell 3000 Elan irradiator (PbGFP-IrrIMM), 
was performed. 
During gliding, sporozoites continuously release vesicles covered with circumsporozoite protein 
(CSP) from their cell surface membrane (Frevert et al., 2005). When gliding on artificial surfaces, such 
as glass coverslips, sporozoites leave behind the CSP vesicles in the shape of a trail that corresponds 
to their patterns of movement (Stewart and Vanderberg, 1988). To access sporozoite gliding motility, 
glass coverslips were coated with an anti-CSP antibody (3D11), where sporozoites were allowed to 
glide freely for 30 min, and were further incubated with the same anti-CSP antibody. Gliding motility 
fitness was then inferred by counting the average number of circle trails left by single sporozoites 
(Figure 6. A). The results showed that the standard radiation dose (16 krad) used to attenuate 
sporozoites has an effect on the parasite’s gliding motility, as both PbGFP-IrrHosp and PbGFP-IrrIMM 
sporozoites showed a significant reduction in gliding motility, of 57 and 46%, respectively, comparing 
to the PbGFP-NIrr sporozoites (Figure 6. A). 
Once in the liver parenchyma, sporozoites migrate through several hepatocytes, disrupting their 
cellular membranes (that can later be resealed, ensuring wounded hepatocytes survival), while 
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traversing through them. Afterwards, sporozoites eventually invade a final hepatocyte with the 
formation of a parasitophorous vacuole (PV), where they dedifferentiate into a developing 
exoerythrocytic form (EEF) (Mota et al., 2001). By infecting hepatoma cells in medium containing 
rhodamine dextran (RD), a dye that is rapidly incorporated by traversed cells and further trapped 
within after membrane reseal (Mota et al., 2001), with PbGFP parasites that constitutively express 
GFP throughout their entire life cycle (Franke-Fayard et al., 2004), it was demonstrated that these 
three biological processes efficacy (migration, invasion and development) can be successfully inferred 
by flow cytometry (Prudêncio et al., 2008). Flow cytometry is a technique that allows a fast and 
quantitative examination of cellular characteristics of thousands of individual cells in a heterologous 
population, including the detection and differentiation cellular subpopulations (Mittag and Tárnok, 
2009). Briefly, flow cytometry analysis of cellular populations is based on the resulting light scattered 
pattern of each individual cell and additionally, if labelled with a fluorophore, on the fluorescence 
intensity that is emitted from the labelled cell, representing the amount of fluorochrome molecules per 
each cell (Mittag and Tárnok, 2009).  
At 2h p.i. (Mota et al., 2001), Huh7 cells, a hepatoma cell line, infected with PbGFP-NIrr, PbGFP-
IrrHosp, or PbGFP-IrrIMM, in RD containing medium, were analysed by flow cytometry, and the 
frequency of RD or GFP positive cells was determined (Figure 6. B). As expected, no significant 
differences were observed between the three groups, confirming that RAS keep their ability infect cells 
comparable to the normal parasites (Figure 6. B). At 48h p.i., a time point suitable to observe P. 
berghei EEF development in these hepatoma cells (Prudêncio et al., 2008), the frequency of GFP 
cells, an indication of whether infected cells are dying with time, and the intensity of GFP per cell, as a 
result of parasite development, were assessed (Figure 6. C). Regarding the number of infected cells, 
which in overall decreases with time as a result of the multiplication of cells in culture, there is a 
decrease in the frequency of GFP positive cells infected with RAS parasites comparing to the NIrr one, 
although this is only significant in the PbGFP-IrrHosp infected cells. This may be explained by the fact 
Figure 6. Irradiated sporozoites fitness in vitro– gliding, migration, 
invasion and development. A) Gliding motility assessment by counting the 
number of circle trails that were left by single sporozoites (15 fields, 20x 
magnification). B) Migration and invasion assessment by flow cytometry. Red 
bars represent the frequency of rhodamine dextran positive cells; green bars 
represent the frequency of GFP positive cells. C) EEF development and 
frequency of infected cells assessment. Development, green bars, is given by 
the geometrical mean of the GFP intensity values within the GFP positive 
cellular population. To only represent development, the geometrical mean of 
the GFP intensity of infected cells at 2h p.i. was subtracted to the values 
obtained at 48h p.i. The frequency of GFP positive cells, dark green dots, 
represent the number of infected cells at 48h p.i. * Significant difference 
between samples (p<0,05, Student’s t test). 
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that from 6h p.i. onwards, RAS-infected hepatocytes start succumbing to apoptosis due to the 
incapacity of the parasite to prevent it (Leirião et al., 2005b; van Dijk et al., 2005). As EEFs develop, 
more copies of GFP are present per cell, and therefore, a higher GFP intensity is detected per infected 
cell. The fluorescence intensity spectrum of a heterogeneous population is plotted as a fluorescence 
intensity histogram, from which the extent of EEF development can be inferred by determining the 
geometrical mean of the distribution. Confirming what was previously reported (Suhrbier et al., 1990; 
Prudêncio et al., 2008), both PbGFP-IrrHosp and PbGFP-IrrIMM showed a severe development 
arrest, presenting GFP intensity values similar to the ones obtained at 2h p.i. (Figure 6. C), meaning 
that the invasive parasites did not developed, while the PbGFP-NIrr developed as expected.  
Altogether, the results confirm that RAS maintain their capacity to migrate and invade hepatocytes 
as the NIrr sporozoites, although their gliding motility was significantly affected. As expected, both 
radiators were able to completely attenuate the parasites, as development was completely arrested in 
both groups of RAS, demonstrating that the irradiation process is reproducible using the two distinct 
irradiator machines. 
IMMUNIZATION WITH ATTENUATED SPOROZOITES – RAS AND GAS 
In two independent experiments, one group of C57BL/6 (ImmC57BL/6) and another of Casp3KO 
(ImmCasp3KO) mice were immunized according to an established three-dose immunization protocol, 
comprising a prime immunization followed by two boosts of 10.000 PbGFP-RAS or 2.000 Pbp36p- 
sporozoites, and subsequently challenged with 10.000 sporozoites (Douradinha et al., 2007). Upon 
challenge, an additional group of non-immunized C57BL/6 mice was also infected, as a control group 
for infection (InfC57BL/6). 
In the experiment where mice were immunized with PbGFP-RAS, the challenge was performed 
with PbGFP sporozoites and, at 40h p.i., liver parasite load was assessed by qRT-PCR. Similar to 
what was previously reported (Douradinha et al., 2007), a marked reduction in liver stage development 
of PbGFP parasites (>99%) was observed in ImmC57BL/6 mice when compared to the non-
immunized, InfC57BL/6 mice, which presented a normal level of infection (Figure 7. A). Such 
significant decrease of parasite development may indicate that sterile protection against infectious 
challenge was achieved in ImmC57BL/6 mice. Interestingly, a significant reduction in parasite load, 
around 94%, was also observed in the ImmCasp3KO mice group (Figure 7. A), although this was not 
as marked as the one observed in the ImmC57BL/6 group, possibly suggesting that immunity 
generated in the ImmCasp3KO mice might not be as efficient as the one generated in the 
ImmC57BL/6 group. Nevertheless, the difference observed between the immunized groups was not 
statistically significant, and sterile protection of ImmCasp3KO mice against the infectious challenge 
was not observed at this stage of parasite infection.  
Moreover, CD8 copies in mice livers, extrapolated to represent the CD8+ T cell load, were also 
quantified by qRT-PCR (Figure 7. B) to infer whether the protection conferred in Casp3KO mice was 
mediated by this T cell population. As expected, InfC57BL/6 mice shown a basal level of CD8 copies, 
representing the level of CD8+ T cells normally present in the liver, as it was too soon for any adaptive 
immune response to be prompted, even one that could be possibly triggered by a normal infection. 
Furthermore, ImmC57BL/6 exhibited a significant increased level of CD8 copies, of approximately 3,3 
times the one of InfC57BL/6 mice (Figure 7. B), corresponding to the cellular immune response that is 
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characteristically generated against challenge after immunization with PbGFP-RAS. Moreover, this 
increase is in accordance with the drastic reduction of parasite load observed in these livers (Figure 7. 
A). Nevertheless, the same was not observed for the ImmCasp3KO group. Despite the reduced 
parasite load, these mice did not present an increased level of CD8 copies. Instead, their level was 
similar to the one observed in InfC57BL/6 mice, and significantly lower (nearly 2,7 times) than the one 
of the ImmC57BL/6 mice, suggesting that the reduction in parasite load observed in ImmCasp3KO 
mice is not mainly due to a CD8+ T cell immune response. Nonetheless, it cannot be assumed that 
these CD8+ T cells are targeting the parasitized cells. For confirmation, an IFN-γ enzyme-linked 
immunosorbent spot (ELISPOT) assay, using peptides from parasite antigens, like CSP, could be 
performed as previously described (Mauduit et al., 2009). Such an assay would allow testing cross-
reactive T cell responses induced by the immunization regimen, through the quantification of parasite 
antigen specific IFN-γ producer CD8+ T cells isolated from the spleen of the different mouse groups 
and, therefore, confirm if the increase of CD8+ T cells in ImmC57BL/6 is composed by CD8+ T cells 
specifically targeting the parasite. Besides, it would also be interesting to perform an Enzyme-linked 
immunosorbent assay (ELISA) to assess the levels of antibodies targeting parasite antigens, like CSP, 
induced by the immunization regimen (Mauduit et al., 2009). Essentially, an ELISA assay would allow 
us to assess if a humoral immune response is also involved and especially, if the reduction in liver 
infection in ImmCasp3KO mice is mediated by an antibody response. 
Protective immunity was ultimately assessed by allowing the challenge infection to progress to the 
Figure 7. Immunization of Casp3KO mice with PbRAS. A) Challenged PbGFP liver stage infection at 40h p.i., assessed by 
qRT-PCR. B) Quantification of CD8 copies in infected livers, reflecting the amount of CD8+ T cells, assessed at 40h p.i. by qRT-
PCR. C) Survival curve representing the % of live mice throughout the blood stage infection follow up. D) Table representing the 
day, average % of parasitemia and the cause of death of the mice represented both in C). * Significant difference between 
samples (p<0,05, Student’s t test). 
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blood stage as detection of developed blood stages of the parasite on blood smears from day 3 p.i. 
onwards constitute the most stringent readout for sterile protection against malaria infection (Mueller 
et al., 2005a). As expected, all InfC57BL/6 mice succumbed with CM within the expected time window 
(Figure 7. C and D). However not all ImmC57BL/6 mice were completely protected against infectious 
challenge. One (n=7) ImmC57BL/6 mouse was not properly immunized and developed malaria, 
nevertheless, with a prolonged pre-patent period compared to the InfC57BL/6 group (7 versus 3 days). 
Although the reasons behind this miss-immunization are unclear, one can speculate that it might have 
been due to an improper administration of the PbGFP-RAS inoculae, rather than due to an improper 
irradiation of the sporozoites because, if it was the case, all mice would have developed disease 
during one of the immunization sessions. Nevertheless, this constitutes a good example of why there 
are so many reservations about using RAS as an antimalarial vaccine. Most importantly, none of the 
ImmCasp3KO mice were completely protected against infection (Figure 7. C and D), as all mice 
presented parasites in the blood by day 4 p.i., one day of delay comparing to the InfC57BL/6 mice. 
Interestingly, three phenotypes were observed. Similarly to what was observed in InfCasp3KO mice 
(Figure 5. D), one mouse (n=5) died within the CM time window without any neurological symptoms, 
while two others died several days later with severe anaemia and hyperparasitemia (Figure 7. D). 
Furthermore, two mice that had presented parasites in the blood (parasitemias of 0,15 to 0,30%) were 
able to clear the parasitemia and survive until the end of the experiment without reappearance of 
infection (Figure 7. D). The reasons behind this phenotype remain unknown, since immunization with 
attenuated sporozoites is recognized to be stage specific and to not confer immunization against blood 
stage forms of the parasite (van Dijk et al., 2005), and therefore, elimination of parasite’s blood stages 
by specific RAS generated immunity in ImmCasp3KO mice is unlikely.  
In the experiment where mice were immunized with 2.000 Pbp36p- sporozoites, challenge was 
performed with PbLuci sporozoites and, 40h p.i., liver stage infection was assessed by real-time in 
vivo imaging. As expected, and similarly to what was observed for immunization with PbGFP-RAS, 
ImmC57BL/6 mice showed a significant reduction (>99%) in liver stage development of PbLuci 
parasites comparing to the InfC57BL/6 mice, while ImmCasp3KO mice presented a less marked 
decrease (<93%) (Figure 8. A). This suggests that immunity generated in ImmCasp3KO mice is less 
efficient than the one generated in ImmC57BL/6 mice. Indeed, when analyzing the data per mouse, 
only 2 of 6 mice presented a clear detectable liver stage infection (Figure 8. Ai), suggesting that some 
ImmCasp3KO mice may have been successfully immunized against further infections. Nevertheless, 
because parasite infection in the liver of these mice is per se variable, one can hypothesize that in 
mice where a normal infection would be low, the reduction of infection due to an even partially 
effective immune response could be enough to decrease parasite load to a level below the detection 
threshold of the real time in vivo imaging system. Therefore, protection was ultimately assessed by 
following the progression of infection in the blood. Both InfC57BL/6 and ImmC57BL/6 groups behaved 
as expected: all InfC57BL/6 mice presented parasites in the blood, and every ImmC57BL/6 mice were 
completely protected from infection (Figure 8. B and C). Nevertheless, only one (n=3) InfC57BL/6 
mouse died from CM while the others succumbed from hyperparasitemia (50 to 70%) and severe 
anaemia (Figure 8. B and C). Unexpectedly, 2 (n=6) ImmCasp3KO mice were completely protected 
from infection, as they have never presented parasitemia until the end of the experiment and in fact, 
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had no detectable parasites in the liver (Figure 8. A, left and bottom image, top mice, and C). All other 
ImmCasp3KO mice succumbed from hyperparasitemia (around 60%) and severe anaemia after day 
18 p.i. Pbp36p- sporozoites have been described to have a more severe deficiency than PbRAS in 
preventing host cell apoptosis (van Dijk et al., 2005), and in fact, this may account for their ability to 
confer complete immunity with such low dose of sporozoites. Possibly, this may allow Pbp36p- 
infected caspase-3 deficient hepatocytes to undergo apoptosis to a larger extent than when infected 
with PbGFP-RAS, and therefore establish, although only in one third, complete immune protection 
against further challenges in ImmCasp3KO mice.  
Casp3KO mice immunized with either PbGFP-RAS or Pbp36p- show a marked decrease in liver 
stage infection. This is an interesting finding since it hypothesized that immunity generated by these 
parasites, primarily mediated by CD8+ T cells, is triggered by apoptotic infected cells (Leirião et al., 
2005b; Jobe et al., 2009). Although caspase-3 deficiency can be compensated either by alternative 
independent pathways or by other effector caspases, caspase-3 has shown to be essential in certain 
processes associated with cell dismantling and further formation of apoptotic bodies (Porter and 
Jänicke, 1999). It is possible that in Casp3KO mice, although infected hepatocytes may undergo 
apoptosis independently from caspase-3, apoptotic bodies filled with parasite antigens from infected 
hepatocytes origin may not being formed, or at least, not at the same rate as in wild type mice. This 
could explain why ImmCasp3KO mice with PbGFP-RAS did not developed a, at least detectable, 
CD8+ T cell mediated immune response, given that the uptake of parasite antigens filled apoptotic 
Figure 8. Immunization of Casp3KO mice with PbRAS. A) Challenged PbLuci liver stage infection at 44h p.i., assessed by 
real time in vivo imaging. Ai) Rainbow images of luminescence in livers of live mice after luciferin injection, showing the relative 
levels of luminescence ranging from low (blue), to medium (green) and to high (yellow/red), and from where the graphic in A) 
was derived. B) Survival curve representing the % of live mice, the same from Ai), throughout the blood stage infection follow 
up. C) Table representing the day, average % of parasitemia and the cause of death of the mice represented both in C). * 
Significant difference between samples (p<0,05, Student’s t test). 
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bodies by DC’s has been associated with the generation of such response (Jobe et al., 2009). 
Nevertheless, immunization of Casp3KO mice confers them partial immunity against further infection, 
although the nature of the involved immune responses is still unknown, and requires further 
investigation. 
IMMUNIZATION OF CHIMERIC MICE WITH PbRAS  
Since Casp3KO mice are deficient in caspase-3 in all their cells and not just in hepatocytes, one 
may argue that ImmCasp3KO mice are only partially protected because their immune system may be, 
to some extent, deficient, and not because of their lower apoptosis of infected liver cells. Nevertheless, 
the phenotype is unlikely to be due to a deficiency in the immune system, since both immature B and 
T cells of Casp3KO mice have been reported to undergo normal apoptosis during differentiation 
(reviewed in Porter and Jänicke, 1999). Moreover, Lakhani et al., 2006, have shown that both 
caspase-3 and caspase-7 are not necessary for the positive and negative selection of T cells, 
suggesting that alternative pathways might be involved. Together, these observations indicate that 
Casp3KO mice may have normal B and T cell mediated responses and that the partial immunity 
generated in this mice upon immunization with attenuated sporozoites may be, in fact, a result of their 
deficiency in the formation of apoptotic bodies from infected hepatocytes. Nonetheless, to exclude the 
involvement of a deficient immune system in the observed phenotypes in ImmCasp3KO mice, bone 
marrow chimeric mice, either expressing caspase-3 exclusively in haematopoietic cells (Casp3KO 
mice reconstituted with C57BL/6 mice bone marrow – ChimCasp3KO) or in non-hematopoietic cells 
(C57BL/6 mice reconstituted with Casp3KO mice bone marrow – ChimC57BL/6), were generated 
(Cunha-Rodrigues et al., 2007). The chimeric groups, along with a C57BL/6 (ImmC57BL/6) and 
another Casp3KO (ImmCasp3KO) groups were immunized with three doses of 10.000 PbGFP-RAS, 
and further challenged with 10.000 PbLuci sporozoites. A non-immunized C57BL/6 group was also 
infected. It was expected that both chimeric groups would respond to infection as their immunized 
control groups have responded in the previous experiments: Chim57BL/6 and ImmC57BL/6 mice 
would be completely immunized and no parasites in the liver and blood would be detected, while 
ChimCasp3KO and ImmCasp3KO mice would only be partially protected, and parasites would be 
detected in the livers and blood of these mice. 
At 48h p.i., the InfC57BL/6 group presented a normal liver parasite load, whereas none of the 
immunized groups presented a clear detectable pre-erythrocytic infection signal (Figure 9. A), 
although two ChimCasp3KO mice showed a faint signal in the abdominal region where the liver 
localizes (Figure 9. A, left image). However, it is not accurate to assume that this fainted signal was in 
fact the parasite developing, as it is too low to have complete certainness. These results might 
suggest that all the immunized groups were successfully protected against subsequent infection, 
although some signal may be below the detection threshold of the real time in vivo imaging system 
and therefore, conclusions can only be taken by following the infection in the blood of these mice. 
As expected, the InfC57BL/6 group presented parasitemia by day 3 p.i. (Figure 9. B), and 
developed CM symptoms by day 7. However, only one (n=3) died from CM. The two others recovered 
from the symptoms and perished later on by hyperparasitemia (Figure 9. C). Moreover, all 
ImmC57BL/6 mice were completely protected against infection, as well as 3 (n=4) of the 
ChimC57BL/6 mice. Unexpectedly, one ChimC57BL/6 mouse presented parasites in the blood, 
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although with a 2 day-delay in the pre-patency period comparing to InfC57BL/6 mice (5 versus 3 days) 
(Figure 9. B). Conversely to what was previously observed in ImmCasp3KO mice, all mice were 
protected against infection, as none presented any parasitemia until day 21 p.i., as well as two (n=4) 
of the ChimCasp3KO mice. Two other ChimCasp3KO mice presented parasites in the blood, also with 
a 2 day-delay pre-patent period, as was observed for the ChimC57BL/6 (Figure 9. B). This may 
indicate that even with a normal immune system, these mice are only partially protected because 
apoptosis of RAS-infected hepatocytes occurs in a lesser extent than in C57BL/6 cells. However, 
overall, these results do not allow us to take any definite conclusions, especially because the 
ImmCasp3KO mice, here as an immunization control, were completely protected from infection. 
Furthermore, the appearance of parasites in the blood of one ChimC57BL/6 mouse does not allow us 
to conclude whereas this was due to a deficiency in the Casp3KO origin immune system or because 
this mouse was improperly immunized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Because the process of creating a chimeric mice is very long (8 weeks), and the immunization 
protocol takes 3 weeks to be completed, the mice herein used were older (5-6 months at infection) 
than the ones used in the previously described immunization experiments (2-3 months at infection). 
This might have had an influence on the observed outcomes, as the immune responses might differ as 
age progresses. An immunization experiment, with more mice per group and with the age range of the 
chimeric mice should therefore be performed in order to check whether the protection outcome is 
similar to the one observed in younger mice. 
 
 
Figure 9. Immunization of chimeric mice with PbRAS. A) Rainbow images of luminescence in livers of live mice after 
luciferin injection, showing the relative levels of luminescence ranging from low (blue), to medium (green) and to high 
(yellow/red). Red circles (regions of interest) surrounding the abdominal region where the luminescence signal is. B) Blood 
stage negative mice curve, representing the day when parasitized mice had parasites in the blood. C) Table representing the 
day, average % of parasitemia and the cause of death of the mice represented in A). 
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DETECTION OF APOPTOSIS IN VIVO – MICE INFECTED WITH PbRAS HAVE HIGHER LEVELS OF 
APOPTOSIS IN THE LIVER  
Recently, through the conjugation of a cell-permeant pan-caspase inhibitor, Z-VAD-fmk 
(carbobenzoxy – valyl-alanyl-aspartic acid – fluoromethyl ketone), that binds to the catalytic site of 
active caspases, with fluorescent probes, such as sulforhodamine (SR) and carboxyfluorescein (FAM), 
a non-toxic poly-caspase reagent for detection of apoptosis in vivo (Fluorescence in vIVO, FLIVOTM), 
was developed (Griffin et al., 2007). Following i.v. injection in mice, FLIVOTM circulates within the 
bloodstream, rapidly diffusing through cells. If active caspases are present, FLIVOTM irreversibly 
establishes covalent bonds with them, inhibiting their enzymatic activity and thus progression of the 
apoptotic process, while unbound reagent is taken with the bloodstream and cleared within one hour 
after injection. As long as the cellular membrane is intact, FLIVOTM remains inside the cell, causing the 
apoptotic cells to fluoresce, giving a direct measure of the caspase activity that was occurring when 
the reagent entered the cell (Immunohistochemistry, 2009). According to the manufacturer, FLIVOTM 
fluorescence can be measured non-invasively by real-time in vivo imaging, or invasively, both by 
microscopic observation of thin tissue sections and flow cytometry (Immunohistochemistry, 2009). 
Using SR-FLIVOTM, we sought to detect differences in apoptosis in the livers of mice infected with 
PbGFP or PbGFP-RAS at 6h p.i., the time point when apoptosis of PbRAS-infected hepatocytes was 
previously reported to occur (van Dijk et al., 2005). Therefore, mice were i.v. infected with 160.000 to 
280.000 sporozoites of PbGFP or PbGFP-RAS, and 5h30min later were i.v. injected with SR-FLIVOTM, 
which was allowed to circulate for 30 min, as recommended by the manufacturer 
(Immunohistochemistry, 2009).  
In a first assay, three groups of C57BL/6 mice, non-infected (N.I.C57BL/6), infected with PbGFP 
(InfC57BL/6), and infected with PbGFP-RAS (Inf-IrrC57BL/6), and another group of Casp3KO mice 
infected with PbGFP-RAS (Inf-IrrCasp3KO), were injected with SR-FLIVOTM (Figure 10. A). Results 
from real-time in vivo imaging shown an increased level of apoptosis in Inf-IrrC57BL/6 mice comparing 
to all the other groups, although this was only statistically significant from the level observed in the 
N.I.C57BL/6 group (Figure 10. A and Ai). Nevertheless, these results suggest that PbGFP-RAS 
parasites are unable to prevent host cell apoptosis. However, the level of apoptosis in Inf-IrrCasp3KO 
mice appears to be slightly higher than the one observed in the InfC57BL/6 mice, suggesting that in 
these mice some PbGFP-RAS parasites are unable to prevent host cell apoptosis, and that other 
caspase-3 independent apoptotic pathways might be involved (Figure 9, A). Because an extra group 
of mice, both non-infected and non-injected with SR-FLIVOTM, was not included as a negative control, 
it was not possible to exclude whether some of the signal observed, for instance in the nose and paws 
of mice, was due to the blood’s auto-fluorescence, or to SR-FLIVOTM still in circulation (Figure 10. Ai). 
Unfortunately, it was not possible to quantify the apoptotic cells either by microscopy and flow 
cytometry.  
In another assay, all groups were constituted by C57BL/6 mice. Negative and positive controls 
were included, respectively, a group that was both not infected nor injected with SR-FLIVOTM, and a 
group that was injected, 5h30min before SR-FLIVOTM, with 5μg of α-Fas antibody, reported to cause 
massive liver failure within hours after injection as a result of the induction of hepatocyte apoptosis 
(Imao et al., 2006). The other three groups of mice were all injected with SR-FLIVOTM, one non-
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infected (N.I.C57BL/6), other infected with PbGFP (InfC57BL/6) and other with PbGFP-RAS (Inf-
IrrC57BL/6) (Figure 10. B and C). Real time in vivo imaging analysis of the negative control mice 
revealed that blood auto-fluorescence signal is captured within the same emission signal range as SR-
FLIVOTM (Figure 10. B), demonstrating that the blood contributes with a background signal that must 
be in the future deducted from the experimental group’s images. In order to avoid blood’s auto-
fluorescence, that could be masking SR-FLIVOTM signal, livers were removed, washed in PBS, and 
further imaged again in the real time in vivo imaging system. Surprisingly, the simple wash with PBS 
was able to clear the background signal originated from the blood, and the differences between all the 
experimental groups was evident (Figure 10. C and Ci). Unfortunately, the positive control group did 
not behave as expected: mice injected with α-Fas antibody presented a lower level of apoptosis than 
all the other experimental groups, except for the InfC57BL/6 one (Figure 10. C and Ci). The reasons 
behind this incapability of the α-Fas antibody to induce massive apoptosis in the liver are unknown, 
although this might have been a consequence of the antibody decrease efficiency due to several 
freeze-thaw cycles, since the same antibody batch has been previously used in the same context with 
the expected outcome. Nevertheless, and although it is not statistically significant, Inf-IrrC57BL/6 mice 
appear to have a higher level of apoptosis comparing to all the other experimental groups, (Figure 10. 
Figure 10. Detection of apoptosis in vivo. A Graphic representing the amount of fluorescence, corresponding to the amount 
of apoptosis, emitted from the abdominal region comprising the liver. Groups that were injected with SR-FLIVOTM are within the 
red dotted box. Red line – background that was deduced from the red signal in the mice noses. Ai Red Hot images of 
fluorescence in livers of live mice 30 min after SR-FLIVOTM injection, showing the relative levels of fluorescence ranging from 
low (dark red), to medium (bright red) and to high (orange/yellow), and from where the graphic in A) was derived. B) Red Hot 
images of blood’s auto-fluorescence non-infected and non- SR-FLIVOTM injected mouse (left), and non-infected but SR-
FLIVOTM -injected mouse. C) Graphic representing the amount of fluorescence emitted by extracted livers. Ci) Red Hot images 
of fluorescence in extracted livers 45 min after SR-FLIVOTM injection, showing the relative levels of fluorescence ranging from 
low (dark red), to medium (bright red) and to high (orange/yellow), and from where the graphic in C) was derived. * Significant 
difference between samples (p<0,05, Student’s t test). 
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C), supporting what was previously observed in the first assay (Figure 10. A). Interestingly, the 
InfC57BL/6 group seemed to show a lower, although not significant, level of apoptosis than the 
N.I.C57BL/6 mice injected with SR-FLIVOTM. This might suggest that infection with infectious parasites 
inhibit host cell apoptosis, as previously reported (Leirião et al., 2005a, van de Sand et al., 2005) 
(Figure 10. C), although it is not known that with this amount of parasite dose the system is sensitive 
enough to detect such phenomenon. Due to technical problems, it was not possible to quantify the 
apoptotic cells either by microscopy and flow cytometry. 
Together, these results appear to, in some extent, support previous observations (van Dijk et al., 
2005; Leirião et al., 2005a; van de Sand et al., 2005): that RAS are unable to prevent the host cell to 
undergo apoptosis, and that infectious parasites prevent host cell apoptosis.  
TRANSGENIC PARASITE – A P. berghei ANKA PARASITE EXPRESSING AND EXPORTING TO THE 
HOST CYTOPLASM A PRO-APOPTOTIC FACTOR 
The hypothesis that the immunity generated by attenuated parasites relies on the formation of 
apoptotic bodies from infected hepatocytes (Leirião et al., 2005b; Jobe et al., 2009), together with the 
results from the immunizations of Casp3KO mice suggesting that caspase-3 mediated apoptosis is, at 
least in part, involved in the acquisition of such protective immunity, has prompt us to design a 
transgenic P. berghei parasite that would promote host cell apoptosis during liver stage infection. We 
aim to infect mice with this parasite and check whether protective immunity against further challenges, 
similar to the one established with the attenuated parasites, is generated. In order to successfully 
construct such parasite, three requirements were needed: a highly efficient pro-apoptotic factor, a 
strong liver stage specific promoter to express it, and an efficient mechanism to export it to the host 
cell cytoplasm. 
Caspases are produced as pro-caspases, and require processing into two subunits to generate the 
fully active enzymes (Colussi et al., 1998). Caspases can be divided into two classes, depending on 
the length of their amino-terminal pro-domains which determine whether they are capable of auto-
activation (class I), or require activation by other activated class I caspases (class II) (Colussi et al., 
1998). Ideally, pro-caspase-3 would have been chosen, as a pro-caspase-3 expressing parasite would 
possibly invert the observed phenotype in the ImmCasp3KO mice and perhaps, confer complete 
immune protection in these mice. However, pro-caspase-3 is a class II caspase, and has been shown 
to be a poor inducer of cell apoptosis when transfected in mammalian cells (Colussi et al., 1998). 
Conversely, pro-caspase-2, a class I caspase, has been reported to successfully auto-activate and 
induce apoptosis in transfected mammalian cells (Colussi et al., 1998), and was therefore chosen as a 
suitable pro-apoptotic factor to construct  the transgenic parasite. 
Plasmodium spp. circumsporozoite protein (CSP) is restrictedly expressed in the parasite’s pre-
erythrocytic stages, coating the sporozoite’s surface as well as the plasma membrane of the 
developing EEF. Moreover, CSP has been also found in the cytoplasm (peak at 1-3h post invasion) of 
infected hepatocytes, where it interacts with the host cell for its own benefit (Singh et al., 2007). 
Recently it was reported that CSP export to the hepatocyte cytoplasm, which requires the traversal of 
the parasitophorous vacuole membrane (PVM), is mediated by pexel motifs (Plasmodium export 
element), present in the protein’s N-terminal region (Singh et al., 2007). Interestingly, these motifs are 
conserved among Plasmodium species CSP, although some like P. berghei and P. falciparum 
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possess two functional pexel motifs, while others, like P. vivax and P. ovale, only have one, allowing 
possibly the translation of findings in rodent models to human parasites. 
In view of pro-caspase-2’s efficiency in inducing apoptosis, the expression of CSP through a strong 
pre-erythrocytic stage specific promoter and its efficient export motif, we sought to design a P. berghei 
transgenic parasite expressing pro-caspase-2 fused with CSP pexel motif under the regulation of the 
CSP promoter (pCS). Once expressed, pro-caspase-2 would be exported to the hepatocyte cytoplasm 
where it would subsequently auto-activate and induce host cell apoptosis, resulting in the formation of 
apoptotic bodies loaded with parasite antigens. 
In order to create a final plasmid, harbouring the fused pCS, pexel motif and pro-caspase-2 
fragments construct, to be inserted into the parasite’s genome (P. berghei ANKA strain), several 
intermediate plasmids were assembled (Figure 11. Plasmid A–F). All plasmids were designed to be 
constructed in a modular fashion to enable the replacement, insertion, deletion or exchange of 
fragments between plasmids. Therefore, the three inserts (pCS, pexel, and pro-caspase-2) were 
amplified with primers containing specific restriction sites present in the two used backbone plasmids 
(pcDNA 3.1 (+) and pVIII), to allow their further insertion in each plasmid. The construction of 
intermediate plasmids is fundamental, as it allows testing in vitro the functionality of the different parts 
of the construct, and whether the different inserts are efficiently expressed and functional when fused 
to each other. Overall, seven plasmids were planned. For the in vitro tests, inserts were introduced 
immediately downstream to the pcDNA 3.1 (+) plasmid T7 promoter, to construct Plasmids A, D and 
E. Plasmid A was aimed to test pro-caspase-2 ability to successfully induce apoptosis, while Plasmids 
D and E were constructed to test the functionality of pro-caspase-2 when fused with the pexel motif, 
and further with GFP, respectively (Figure 11.). In order to obtain the final plasmid to be transfected 
into the parasite, the pVIII plasmid, which contains one of the most commonly used selectable 
markers in Plasmodium transfection, the altered Toxoplasma gondii dihydrofolate reductase-
thymidylate synthase (DHFR-TS) gene, that confers resistance to the antimalarial drug pyrimethamine 
Figure 11. Transgenic, pro-apoptotic parasite. Plasmid A comprises the plasmid pcDNA 3.1 (+) with the inserted pro-
caspase-2 gene. Plasmid B encompasses the plasmid pVIII with the inserted pCS and pexel motif. Plasmid C results from the 
insertion of the pro-caspase-2 fragment that was excised from Plasmid A, into Plasmid B to have has a final product the fused 
pCS, pexel motif and pro-caspase-2 construct. Plasmid D results from the insertion of the fragment pexel and pro-caspase-2 
from Plasmid C into the pcDNA 3.1 (+) plasmid. Plasmid E outcomes from the insertion of a GFP fragment into Plasmid D, 
downstream to the pro-caspase-2 fragment. Plasmid F results from the insertion of the GFP fragment into Plasmid C, 
downstream to pro-caspase-2 fragment. Depending on whether the fused fragment of pCS, pexel and pro-caspase-2 with GFP 
still succeed to promote cell apoptosis, Plasmid C or Plasmid F will be transfected into P. berghei ANKA blood schizonts.  
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(Balu and Adams, 2007), was used. This allows the selection of the transgenic parasites in a 
heterogeneous parasite population with pyrimethamine, as the final construct inserted into the pVIII 
plasmid will be transfected in a pyrimethamine susceptible parasite line. Plasmid B was therefore 
constructed by inserting the fused pCS and pexel motif fragment into the pVIII plasmid (Figure 11.). If 
Plasmid A shows to be able to induce apoptosis in transfected cells, the pro-caspase-2 fragment is 
going to be excised and inserted into Plasmid B, downstream to the pexel motif fragment, resulting in 
a fused construct of the three fragments (Plasmid C). Because it possesses all the inserts fused and 
an inserted single cutter site within the pCS fragment, that allows its linearization and further 
transfection into the parasite, Plasmid C is ready to be transfected. Nevertheless, depending on 
whether Plasmid E testing reveals that pro-caspase-2 fused to GFP is functional, the GFP fragment 
will be further inserted into Plasmid C to generate Plasmid F, and therefore, instead of Plasmid C, it 
will be transfected into the parasite (Figure 11.). The tagging of the final construct, pCS, pexel motif 
and pro-caspase-2, with GFP would allow the visualization of caspase-2::GFP in the hepatocytes 
infected with the transgenic parasite. Upon transfection, by electroporation of blood schizonts, Plasmid 
C or F will be integrated into the parasite genome by homologous recombination, where the wild type 
CSP gene will be kept intact and functional, and the plasmid will be placed upstream to it. Afterwards, 
transgenic blood schizonts will be injected into BALB/c mice, which do not develop CM but instead, 
hyperparasitemia, to generate more transgenic parasites by selecting them with pyrimethamine. 
Subsequently, mosquitoes will be infected, the transgenic parasite life cycle characterized, and 
C57BL/6 as well as Casp3KO mice will be infected, with a number of doses to be defined, to infer if 
this transgenic parasite is able to confer them complete and sterile protection against further 
challenges with WT sporozoites.  
Up to present, Plasmids A and B were successfully constructed. To test Plasmid A, Hepa 1-6 cells 
were transfected, and apoptosis was further assessed by AlamarBlue® assay at 24, 25, 26, 30 and 
50h post transfection. The AlamarBlue® assay allows a very simple assessment of cell viability. Its 
active ingredient, resazurin, is a non-toxic cell permeable compound that, upon entering cells, is 
reduced to resorufin, a highly fluorescent compound. Fluorescence is then measured and its intensity 
correlates with the amount of living cells (Invitrogen, 2008). Unfortunately, no decrease in cell viability 
was reported in this assay, as at all time points cells transfected with Plasmid A had a similar level of 
fluorescence as the non-transfected cells and cells transfected with pcDNA 3.1 (+) alone, respectively, 
the negative and the transfection control groups (Figure 12.). Therefore, further microscopy tests, 
such as the TUNEL assay, and staining of active caspase-2 or caspase-3, or detection of pro-
caspase-2 and active caspase-2 by western blot, must be performed to confirm whether pro-caspase-
2 is being over expressed and activated, and if it is able to induce apoptosis of the transfected cells. 
 
Figure 12. Plasmid A in vitro testing. Hepa 1-6 cells were 
transfected with Plasmid A and cell viability assessed by 
alamarBlue® at 24, 25, 26, 30 and 50h p.i. No differences 
are observed between the different conditions at the given 
time points.  
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CONCLUSIONS AND FUTURE PERSPECTIVES 
Since early as the 1970’s, it is known that immunization of humans with Plasmodium falciparum 
sporozoites, attenuated by radiation (PfRAS), is able to induce and establish a long-lasting and 
completely sterile immune response against further infection with infectious P. falciparum sporozoites 
(Clyde et al., 1973). Presently, and after decades of deep research, a vaccine based on such principle 
is being tested in phase I clinical trials (Vaughan et al., 2010). However, the exact mechanisms by 
which such strong and efficient immune responses are triggered remain unknown. In the last years, 
observations that cells infected with attenuated parasites undergo apoptosis (Leirião et al., 2005b; van 
Dijk et al., 2005) prompted the elaboration of the hypothesis that this event is the player in the 
induction of the immune response: apoptosis of infected cells leads to the formation of apoptotic 
bodies filled with parasite antigens. These apoptotic bodies can be therefore phagocytosed by antigen 
presenting cells that will, afterwards, present these exogenous antigens to the immune system and 
thus, induce the immune responses responsible for the complete protection against further infections.  
The present work purposed precisely to elucidate whereas apoptosis of cells infected with 
attenuated parasites is involved in the generation of the effective immune protection, triggered upon 
immunization with these parasites. The results herein presented appear to support the proposed 
hypothesis: livers of infected mice with P. berghei radiation attenuated sporozoites (RAS) present a 
higher level of apoptosis, and the abrogation, or at least the decrease, of caspase-3 mediated 
apoptosis in the livers of C57BL/6 caspase-3 deficient mice results in the partial establishment of 
protective immunity by attenuated sporozoites. Although it was not possible to completely exclude that 
the acquisition of partial immunity was due to a deficiency in the immune system of the used mice, it 
appears that the observed phenotype is due to the reduced level of apoptosis in these mice livers, 
instead of a deficiency in their immune system. Therefore, in the near future, another chimeric mice 
immunization experiment will be performed, with more mice per group. Moreover, other immunization 
experiments, with more Casp3KO mice per group (from the same age range as the mice used in the 
chimeric experiment) will be also performed, in order to elucidate and establish the phenotype 
observed in the immunized Casp3KO mice.  
To further test the involvement of apoptosis of infected cells, a transgenic P. berghei ANKA 
parasite, capable of inducing host cell apoptosis during its pre-erythrocytic stages was idealized. We 
perspective that this parasite, which is not yet completely constructed, will be able to induce protection 
against further infections, similarly to the one induced by immunization with attenuated sporozoites. 
Moreover, we thought of performing more fundamental assays, for instance, to set up the time course 
of persistence of attenuated sporozoites inside the host cell and when do they start to be unable to 
prevent host cell to undergo apoptosis both in C57BL/6 and Casp3KO mice primary hepatocytes. After 
being elucidated the time point p.i. where apoptosis of RAS-infected cells is at maximum, other assays 
aiming to observe apoptosis of RAS-infected hepatocytes in vivo and the presence or not of antigen 
presenting cells, both in C57BL/6 and Casp3KO mice, will be performed, such the TUNEL assay in 
liver histological sections.  
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